var docs;if (!docs) docs =[]; docs["57"]={"5700":"<p><b>Title</b> Methylene Blue / Tricyclic Antidepressants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of tricyclic antidepressants (TCAs) for a period of 2 weeks prior to administration of methylene blue. [Note: Canadian product labeling differs slightly in that it recommends consideration of serotonin reuptake inhibitor discontinuation for 4-5 half lives prior to methylene blue.] In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue the TCA immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last TCA dose, or 24 hours after the last dose of methylene blue, whichever comes first. TCA treatment may be resumed 24 hours after the last dose of methylene blue.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5701":"<p><b>Title</b> Methylene Blue / TraZODone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> TraZODone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of trazodone for a period of 2 weeks prior to administration of methylene blue. [Note: Canadian product labeling differs slightly in that it recommends consideration of serotonin reuptake inhibitor discontinuation for 4-5 half lives prior to methylene blue.] In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue trazodone immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last trazodone dose, or 24 hours after the last dose of methylene blue, whichever comes first. Trazodone treatment may be resumed 24 hours after the last dose of methylene blue.</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5702":"<p><b>Title</b> Methylene Blue / Nefazodone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nefazodone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of nefazodone for a period of 2 weeks prior to administration of methylene blue. [Note: Canadian product labeling differs slightly in that it recommends consideration of serotonin reuptake inhibitor discontinuation for 4-5 half lives prior to methylene blue.] In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue nefazodone immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last nefazodone dose, or 24 hours after the last dose of methylene blue, whichever comes first. Nefazodone treatment may be resumed 24 hours after the last dose of methylene blue.</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5706":"<p><b>Title</b> Disopyramide / Lurasidone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This theoretical interaction consideration applies only in the setting of acute lurasidone overdose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lurasidone may enhance the QTc-prolonging effect of Disopyramide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to disopyramide in patients with acute lurasidone overdose. If disopyramide treatment cannot be avoided, monitor for excessive QTc interval prolongation.</p> \n<p><b>Discussion</b> Lurasidone prescribing information states that disopyramide, procainamide, and quinidine carry a theoretical risk of additive QT interval prolonging effects in patients with acute lurasidone overdose.<sup>1</sup> Therefore alternative antiarrhythmic agents should be considered, and QTc interval should be closely monitored if any of the listed agents are required.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Latuda (lurasidone). Marlborough, MA: Sunovion Pharmaceuticals Inc., October 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5707":"<p><b>Title</b> QuiNIDine / Lurasidone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This theoretical interaction consideration applies only in the setting of acute lurasidone overdose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lurasidone may enhance the QTc-prolonging effect of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to quinidine in patients with acute lurasidone overdose. If quinidine treatment cannot be avoided, monitor for excessive QTc interval prolongation.</p> \n<p><b>Discussion</b> Lurasidone prescribing information states that disopyramide, procainamide, and quinidine carry a theoretical risk of additive QT interval prolonging effects in patients with acute lurasidone overdose.<sup>1</sup> Therefore alternative antiarrhythmic agents should be considered, and QTc interval should be closely monitored if any of the listed agents are required.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Latuda (lurasidone). Marlborough, MA: Sunovion Pharmaceuticals Inc., October 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5708":"<p><b>Title</b> Procainamide / Lurasidone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This theoretical interaction consideration applies only in the setting of acute lurasidone overdose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lurasidone may enhance the QTc-prolonging effect of Procainamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to procainamide in patients with acute lurasidone overdose. If procainamide treatment cannot be avoided, monitor for excessive QTc interval prolongation.</p> \n<p><b>Discussion</b> Lurasidone prescribing information states that disopyramide, procainamide, and quinidine carry a theoretical risk of additive QT interval prolonging effects in patients with acute lurasidone overdose.<sup>1</sup> Therefore alternative antiarrhythmic agents should be considered, and QTc interval should be closely monitored if any of the listed agents are required.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Latuda (lurasidone). Marlborough, MA: Sunovion Pharmaceuticals Inc., October 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5710":"<p><b>Title</b> Lurasidone / DOPamine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This theoretical interaction consideration applies only in the setting of acute lurasidone overdose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> DOPamine may enhance the hypotensive effect of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid dopamine in patients with hypotension and circulatory collapse caused by acute lurasidone overdose.</p> \n<p><b>Discussion</b> Lurasidone prescribing information states that epinephrine and dopamine should not be used for hypotension and circulatory collapse caused by acute lurasidone overdose, as beta stimulation could theoretically worsen hypotension brought about by lurasidone alpha blockade.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Latuda (lurasidone). Marlborough, MA: Sunovion Pharmaceuticals Inc., October 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5712":"<p><b>Title</b> Phenytoin / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FLUoxetine may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased concentrations/toxic effects of phenytoin if fluoxetine is initiated/dose increased, or decreased concentrations/effects if fluoxetine is discontinued/dose decreased. Adjust phenytoin dose as needed.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations have been noted to increase by 60% to 400% within 10 days of initiating fluoxetine therapy.<sup>1,2</sup> Several case reports have described development of symptoms of phenytoin toxicity with this combination.<sup>3,4</sup> Additionally, discontinuation of fluoxetine in a phenytoin-maintained patient resulted in a 58% reduction in total phenytoin concentration.<sup>5</sup> The likely primary mechanism of interaction between these agents is fluoxetine inhibition of CYP2C19 and/or 2C9 mediated phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Woods DJ, Coulter DM, and Pillans P, “Interaction of Phenytoin and Fluoxetine,” <i>N Z Med J</i>, 1994, 107:970. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8295752\">[PubMed 8295752]</a></p>\n<p>2. Jalil P, “Toxic Reaction Following the Combined Administration of Fluoxetine and Phenytoin: Two Case Reports,” <i>J Neurol Neurosurg Psychiat</i>, 1992, 55:412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1602320\">[PubMed 1602320]</a></p>\n<p>3. Darley J, “Interaction Between Phenytoin and Fluoxetine,” <i>Seizure</i>, 1994 Jun;3(2):151-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8081642\">[PubMed 8081642]</a></p>\n<p>4. Shader RI, Greenblatt DJ and von Moltke LL, “Fluoxetine Inhibition of Phenytoin Metabolism,” <i>J Clin Psychopharmacol</i>, 1994, 14(6):375-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7884016\">[PubMed 7884016]</a></p>\n<p>5. Shad MU and Preskorn SH, “Drug-Drug Interaction in Reverse: Possible Loss of Phenytoin Efficacy as a Result of Fluoxetine Discontinuation,” <i>J Clin Psychopharmacol</i>, 1999, 19(5):471-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10505590\">[PubMed 10505590]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5713":"<p><b>Title</b> Sertraline / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sertraline may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Sertraline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced clinical response to sertraline if phenytoin is initiated/dose increased, or increased response/toxicity if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> A review of therapeutic drug monitoring data indicated that dose-corrected sertraline serum concentrations in patients receiving phenytoin or carbamazepine were approximately 32% of those seen in patients not receiving phenytoin or carbamazepine.<sup>1</sup> <br><br>Additionally, two case reports describe patients whose serum phenytoin concentrations increased (by 22% and 450%) following initiation of sertraline.<sup>1</sup> However, a clinical study demonstrated no significant change in phenytoin (100 mg orally three times daily) pharmacokinetic parameters in healthy volunteers given sertraline (200 mg daily for 10 days, following a 7 day dose escalation).<sup>2</sup> <br><br>The likely primary mechanism of interaction between these agents is phenytoin induction of non-CYP2D6 sertraline metabolic pathways (e.g., CYP2B6, 2C9, 2C19, and 3A4). Sertraline may inhibit CYP2C19 and/or 2C9 mediated phenytoin metabolism as well, but effects appear to be minor in most cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pihlsgard M and Eliasson E, “Significant Reduction of Sertraline Plasma Levels by Carbamazepine and Phenytoin,” <i>Eur J Clin Pharmacol</i>, 2002, 57(12):915-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936714\">[PubMed 11936714]</a></p>\n<p>2. Haselberger MB, Freedman LS, and Tolbert S, “Elevated Serum Phenytoin Concentrations Associated With Coadministration of Sertraline,” <i>J Clin Psychopharmacol</i>, 1997, 17(2):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10950473\">[PubMed 10950473]</a></p>\n<p>3. Rapeport WG, Muirhead DC, Williams SA, et al, “Absence of Effect of Sertraline on the Pharmacokinetics and Pharmacodynamics of Phenytoin,” <i>J Clin Psychiatry</i>, 1996, 57(Suppl 1):24-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8617708\">[PubMed 8617708]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5714":"<p><b>Title</b> Warfarin / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nelfinavir may decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor INR in warfarin treated patients during treatment with nelfinavir, particularly during warfarin initiation and following any changes in nelfinavir dose.</p> \n<p><b>Discussion</b> In February 2011, an update to nelfinavir U.S. prescribing information was approved that advises close monitoring of international normalized ratio (INR) in patients receiving warfarin, due to a potential for nelfinavir to alter warfarin concentrations.<sup>1</sup> Additionally, two case reports describe patients receiving combination antiretroviral regimens containing nelfinavir who required higher than expected (10-12.5 mg/day) warfarin maintenance doses to maintain INR between 2 and 3.<sup>2</sup> However, the link between apparent decreased INR response to warfarin and nelfinavir treatment specifically is questionable given a number of additional medications involved in these cases.<br><br>The most likely mechanism of interaction between these agents is nelfinavir induction of CYP2C9 mediated S-warfarin (the more potent enantiomer) metabolism. This could theoretically decrease S-warfarin concentrations and increase warfarin dose requirements. It is also possible that nelfinavir inhibition of CYP enzymes mediating warfarin metabolism (e.g., CYP1A2, 2C9, 3A4) may actually increase warfarin concentrations before induction effects take hold, although such effects have not been described clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., February 2011.</p>\n<p>2. Fulco PP, Zingone MM and Higginson RT, “Possible Antiretroviral Therapy-Warfarin Drug Interaction,” <i>Pharmacotherapy</i>, 2008, 28(7):945-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18576910\">[PubMed 18576910]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5715":"<p><b>Title</b> GlipiZIDE / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Posaconazole may enhance the hypoglycemic effect of GlipiZIDE. Posaconazole may increase the serum concentration of GlipiZIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased blood glucose concentrations during concomitant treatment with posaconazole and glipizide.</p> \n<p><b>Discussion</b> Posaconazole prescribing information recommends monitoring of blood glucose concentrations when posaconazole and glipizide are used concomitantly.<sup>1</sup> In a crossover study in 12 healthy volunteers, administration of posaconazole (400 mg orally twice daily for 10 days) increased glipizide (10 mg single oral dose) maximum concentration and AUC by less than 10% each, and decreased maximum and minimum blood glucose concentrations by 13-15%.<sup>2</sup><br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering Corporation, 9/2010.</p>\n<p>2. Courtney R, Sansone A, Statkevich P, et al, “Assessment of The Pharmacokinetic (PK), Pharmacodynamic (PD) Interaction Potential Between Posaconazole and Glipizide in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2003, 73(2):P45.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5716":"<p><b>Title</b> Phenytoin / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased concentrations/toxic effects of phenytoin if fluvoxamine is initiated/dose increased, or decreased concentrations/effects if fluvoxamine is discontinued/dose decreased. Adjust phenytoin dose as needed.</p> \n<p><b>Discussion</b> A case report describes a patient whose phenytoin serum concentration increased roughly 3 fold following initiation of fluvoxamine.<sup>1</sup> Genotyping detected no CYP2C9 or 2C19 loss of function variants. The likely primary mechanism of interaction between these agents is fluvoxamine inhibition of CYP2C19 mediated phenytoin metabolism. Fluvoxamine inhibition of CYP2C9 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mamiya K, Kojima K, Yukawa E, et al, “Phenytoin Intoxication Induced by Fluvoxamine,” <i>Ther Drug Monit</i>, 2001, 23(1):75-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11206048\">[PubMed 11206048]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5717":"<p><b>Title</b> Vilazodone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the maximum adult vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In 2 pharmacokinetic studies of healthy volunteers, ketoconazole (200 mg daily) increased the vilazodone AUC 42% to 51% and increased the vilazodone maximum serum concentration 38% to 48%.<sup>1</sup><br><br>Vilazodone prescribing information states that because strong CYP3A4 inhibitors increase vilazodone exposure, the vilazodone dose should not exceed 20 mg daily when combined with strong CYP3A4 inhibitors.<sup>2</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for vilazodone metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Boinpally R, Gad N, Gupta S, Periclou A. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. <i>Clin Ther</i>. 2014;36(11):1638-1649. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25236915\">[PubMed 25236915]</a></p>\n<p>2. Viibryd (vilazodone) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5718":"<p><b>Title</b> Vilazodone / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of vilazodone if combined with moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The effect of moderate CYP3A4 inhibitors on vilazodone exposure has not been evaluated in a clinical study. However, in 2 pharmacokinetic studies of healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (200 mg daily) increased the vilazodone AUC 42% to 51% and increased the vilazodone maximum serum concentration 38% to 48%.<sup>1</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for vilazodone metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Boinpally R, Gad N, Gupta S, Periclou A. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. <i>Clin Ther</i>. 2014;36(11):1638-1649. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25236915\">[PubMed 25236915]</a></p>\n<p>2. Viibryd (vilazodone) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5719":"<p><b>Title</b> Magnesium Salts / Alfacalcidol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alfacalcidol may increase the serum concentration of Magnesium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving alfacalcidol. If magnesium-containing products must be used with alfacalcidol, serum magnesium concentrations should be monitored closely.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> Alfacalcidol product monograph recommends avoiding magnesium-containing antacids due to risks of hypermagnesemia.<sup>1</sup> Following administration, alfacalcidol undergoes hepatic conversion to 1,25-dihydroxycholecaliferol (calcitriol). Studies in humans<sup>2</sup> and rats<sup>3</sup> have shown that calcitriol stimulates magnesium absorption in the intestine<sup>2</sup> and colon.<sup>3</sup> Studies in mouse distal convoluted tubule cells have also shown that calcitriol stimulates magnesium uptake in these cells,<sup>4</sup> which are known to play an important role in magnesium reabsorption.<br><br>The population likely to be at the greatest risk for developing hypermagnesemia due to this interaction are those with chronic renal failure and/or those on chronic dialysis, given alterations in magnesium, calcium, and phosphorous handling common in such patients. Though magnesium salts are generally considered to have no advantage over other phosphate binders in these patients,<sup>5</sup> reports of successful combined use of magnesium products and calcitriol in both chronic renal failure<sup>6</sup> and chronic hemodialysis patients<sup>7</sup> do exist.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010.</p>\n<p>2. Ruggiero M, Brunese M, Morelli S, et al, “Plasma 1,25 Hydroxycholecalciferol Concentrations and Net Intestinal Calcium, Phosphate and Magnesium Absorption in Man,” <i>Boll Soc Ital Biol Sper</i>, 1981, 57(7):791-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6895034\">[PubMed 6895034]</a></p>\n<p>3. Karbach U, Ewe K, “Calcium and Magnesium Transport and Influence of 1,25-Dihydroxyvitamin D3. In Vivo Perfusion Study at the Colon of the Rat,” <i>Digestion</i>, 1987, 37(1):35-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3609503\">[PubMed 3609503]</a></p>\n<p>4. Ritchie G, Kerstan D, Dai LJ, et al, “1,25(OH)(2)D(3) Stimulates Mg2+ Uptake into MDCT Cells: Modulation by Extracellular Ca2+ and Mg2+,” <i>Am J Physiol Renal Physiol</i>, 2001, 280(5):F868-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11292630\">[PubMed 11292630]</a></p>\n<p>5. Loghman-Adham M, “Safety of New Phosphate Binders for Chronic Renal Failure,” <i>Drug Saf</i>, 2003, 25(15):1093-115.</p>\n<p>6. Lindeman RD, “Chronic Renal Failure and Magnesium Metabolism,” <i>Magnesium</i>, 1986, 5(5-6):293-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3807422\">[PubMed 3807422]</a></p>\n<p>7. Delmez JA, Kelber J, Norword KY, et al, “Magnesium Carbonate as a Phosphorus Binder: A Prospective, Controlled, Crossover Study,” <i>Kidney Int</i>, 1996, 49(1):163-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8770963\">[PubMed 8770963]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5720":"<p><b>Title</b> Sulfonylureas / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the hypoglycemic effect of Sulfonylureas. Nonsteroidal Anti-Inflammatory Agents may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> A case report and a number of clinical studies describe glycemic effects of combining nonsalicylate NSAIDs with sulfonylureas. The case report describes a patient receiving glyburide in whom single doses of ibuprofen reproducibly led to development of hypoglycemia.<sup>1</sup> The clinical studies, briefly, describe the following: ibuprofen had no impact on fasting or postprandial blood glucose concentrations in patients receiving chlorpropamide;<sup>2</sup> tolmetin had no impact on blood and urine glucose patterns in patients receiving glyburide;<sup>3</sup> naproxen had no impact on fasting blood glucose and response to glucose tolerance test in patients receiving tolbutamide;<sup>4</sup> ibuprofen did not significantly affect glyburide insulin response, and was associated with small changes in some glucose tolerance test parameters (e.g. decreased glucose AUC) but not all (e.g. maximum glucose concentration);<sup>5</sup> pretreatment with indomethacin appeared to decrease fasting blood glucose lowering effects of tolbutamide;<sup>6</sup> and treatment with sulindac led to slightly lower (-7.6 mg/dL) fasting and higher (+4.9 mg/dL) postprandial plasma glucose concentrations in patients receiving tolbutamide.<sup>7</sup><br><br>Three of these studies measured for changes in sulfonylurea pharmacokinetic parameters during nonsalicylate NSAID treatment, and found none.<sup>4,5,7</sup> One showed a small increase in glyburide free fraction with concomitant ibuprofen.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sone H, Takahashi A and Yamada N, “Ibuprofen-Related Hypoglycemia in a Patient Receiving Sulfonylurea,” <i>Ann Intern Med</i>, 2001, 134(4):344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11182854\">[PubMed 11182854]</a></p>\n<p>2. Shah SJ, Bhandarkar SD and Satoskar RS, “Drug Interaction Between Chlorpropamide and Non-Steroidal Anti-Inflammatory Drugs, Ibuprofen and Phenylbutazone,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1984, 22(9):470-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6500764\">[PubMed 6500764]</a></p>\n<p>3. Chlud K and Kaik B, “Clinical Studies of the Interaction Between Tolmetin and Glibenclamide,” <i>Int J Clin Pharmacol Biopharm</i>, 1977, 15(9):409-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=410740\">[PubMed 410740]</a></p>\n<p>4. Whiting B, Williams RL, Lorenzi M, et al, “Effect of Naproxen on Glucose Metabolism and Tolbutamide Kinetics and Dynamics in Maturity Onset Diabetics,” <i>Br J Clin Pharmacol</i>, 1981, 11(3):295-302. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7213531\">[PubMed 7213531]</a></p>\n<p>5. Diwan PV and Kulkarni DR, “Influence of Non-Steroidal Anti-Inflammatory Agents on Tolbutamide Hypoglycaemia,” <i>Indian J Med Res</i>, 1983, 78:147-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6642594\">[PubMed 6642594]</a></p>\n<p>6. Ryan JR, Jain AK, McMahon FG, et al, “On the Question of an Interaction Between Sulindac and Tolbutamide in the Control of Diabetes,” <i>Clin Pharmacol Ther</i>, 1977, 21(2):231-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=837641\">[PubMed 837641]</a></p>\n<p>7. Kubacka RT, Antal EJ, Juhl RP, et al, “Effects of Aspirin and Ibuprofen on the Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Subjects,” <i>Ann Pharmacother</i>, 1996, 30(1):20-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8773160\">[PubMed 8773160]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5721":"<p><b>Title</b> Roflumilast / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast. The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Total PDE4 inhibitory activity (tPDE4i) was decreased by an average of 58%, reflecting both an average 80% decrease in roflumilast AUC and an average 56% decrease in roflumilast N-oxide AUC, when rifampin (600 mg/day) was coadministered with a single dose of oral roflumilast (500 mcg) in a non-randomized crossover study in 16 healthy volunteers.<sup>1,2</sup> This decrease in tPDE4i and roflumilast/roflumilast N-oxide exposure is likely related to rifampin-mediated induction of the CYP3A4 and CYP1A2 enzymes responsible for roflumilast metabolism.<sup>1,2,3</sup> U.S. prescribing information states that concomitant use of roflumilast with strong CYP3A4 inducers in not recommended.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nassr N, Huennemeyer A, von Richter O, et al, “Effects of Rifampicin on the Pharmacokinetics of Roflumilast and Roflumilast N-oxide in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2009, 68(4):580-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19843061\">[PubMed 19843061]</a></p>\n<p>2. Product Monograph. Daxas (roflumilast). Oakville, Ontario, Canada: Nycomed Canada Inc., November 2010.</p>\n<p>3. Prescribing information. Daliresp (roflumilast). St. Louis, MO: Forest Laboratories, Inc., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5722":"<p><b>Title</b> Vitamin D Analogs / Mineral Oil</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Applies only to oral administration of these agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mineral Oil may decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor plasma calcium concentrations in patients receiving combined therapy with mineral oil and Vitamin D analogs. Avoid concomitant administration to avoid the risk for decreased absorption of the Vitamin D analog. Specific recommendations regarding the separation of administration of these agents are generally not defined, but paricalcitol labeling recommends administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of mineral oil. It would seem prudent to similarly separate the administration of other vitamin D analogs from mineral oil by several hours to minimize the risk of an interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.</p>\n<div>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcitriol (Systemic), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol<br><b>Exceptions</b> Calcipotriene, Calcitriol (Topical), Tacalcitol</p>\n</div> \n<p><b>Discussion</b> The prescribing information for several vitamin D analogs warns that mineral oil may interfere with their absorption.<sup>1,2,3,4</sup> Specific recommendations regarding the separation of administration of these agents are generally not defined, but paricalcitol labeling recommends administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of mineral oil.<sup>3</sup> It would seem prudent to similarly separate the administration of other vitamin D analogs from mineral oil by several hours to minimize the risk of an interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; February 2011.</p>\n<p>2. Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2007.</p>\n<p>3. Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016. </p>\n<p>4. One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario:LEO Pharma Inc.; March 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5723":"<p><b>Title</b> Eltrombopag / Selenium</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of selenium are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Selenium may decrease the serum concentration of Eltrombopag. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation (e.g., selenium-containing products).</p> \n<p><b>Discussion</b> The eltrombopag AUC was an average of 70% lower following administration of eltrombopag together with an antacid containing aluminum hydroxide, magnesium carbonate, and sodium alginate.<sup>1,2</sup> Similarly, eltrombopag AUC was an average of 75% lower following administration of eltrombopag with a high-calcium meal.<sup>1</sup> The eltrombopag AUC was 47% lower when administered 2 hours after a high-calcium meal, and the eltrombopag AUC was 20% lower when administered 2 hours before a high-calcium meal.<sup>1</sup><br><br>It is likely that this interaction represents chelation, where the polyvalent cation and eltrombopag bind to one another, forming a nonabsorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015.</p>\n<p>2. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. <i>Clin Ther</i>. 2009;31(4):764-776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19446149\">[PubMed 19446149]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5724":"<p><b>Title</b> Eltrombopag / Zinc Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of zinc salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zinc Salts may decrease the serum concentration of Eltrombopag. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation (e.g., zinc-containing products).</p>\n<div>\n <p><b>Zinc Salts Interacting Members</b> Polaprezinc, Zinc Acetate, Zinc Chloride, Zinc Gluconate, Zinc Sulfate</p>\n</div> \n<p><b>Discussion</b> The eltrombopag AUC was an average of 70% lower following administration of eltrombopag together with an antacid containing aluminum hydroxide, magnesium carbonate, and sodium alginate.<sup>1,2</sup> Similarly, eltrombopag AUC was an average of 75% lower following administration of eltrombopag with a high-calcium meal.<sup>1</sup> The eltrombopag AUC was 47% lower when administered 2 hours after a high-calcium meal, and the eltrombopag AUC was 20% lower when administered 2 hours before a high-calcium meal.<sup>1</sup><br><br>It is likely that this interaction represents chelation, where the polyvalent cation and eltrombopag bind to one another, forming a nonabsorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015.</p>\n<p>2. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. <i>Clin Ther</i>. 2009;31(4):764-776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19446149\">[PubMed 19446149]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5725":"<p><b>Title</b> Vitamin D Analogs / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Applies only to oral administration of these agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (ie, 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea.<sup>1,2,3</sup> Specific recommendations regarding the separation of administration of these agents are generally not defined. Paricalcitol labeling recommends administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of cholestyramine or similar products,<sup>4</sup> and colesevelam labeling recommends giving drugs with a known interaction or unclear interaction potential at least 4 hours prior to colesevelam.<sup>5</sup> It would seem prudent to similarly separate the administration of other vitamin D analogs from bile acid sequestrants by several hours to minimize the risk of an interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcitriol (Systemic), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol<br><b>Exceptions</b> Calcipotriene, Calcitriol (Topical), Tacalcitol</p>\n</div> \n<p><b>Discussion</b> The prescribing information for several vitamin D analogs warn that bile acid sequestrants (eg, cholestyramine) may impair their absorption.<sup>4,6,7,8,9</sup> Several studies have suggested that bile acid sequestrants can impair the intestinal absorption of vitamin D, though there are relatively few studies in adults that have addressed this interaction. One study of 18 children receiving comparatively high doses of cholestyramine (average dose 0.6 g/kg/d, roughly equivalent to 30-40 g/d in adults) for 1 to 2.5 years reported no change in mean calcium or alkaline phosphatase concentrations over the study period. Vitamin D concentrations were not measured directly, but it was suggested that observed changes in inorganic phosphorous concentrations (significantly decreased from baseline) could have resulted from increased parathyroid hormone concentrations that occurred secondary to impaired absorption of vitamin D.<sup>2</sup> Two case reports and several animal studies support the theory that bile acid sequestrants can impair vitamin D absorption. Both case reports describe patients with prior ileal resections who developed osteomalacia that was attributed to cholestyramine therapy.<sup>10,11</sup> Studies in rats have shown that steatorrhea-inducing doses of cholestyramine impaired vitamin D<sub>3</sub> absorption and was associated with altered calcium handling.<sup>3,12</sup><br><br>Conversely, two separate long-term clinical studies found that cholestyramine (24 g/d) treatment for up to 7-10 years was not associated with any changes in plasma concentrations of calcium, phosphorous, calcifediol, 25-hydroxy-vitamin D<sub>2</sub>, or calcitriol.<sup>13,14</sup> Another study in children with hypercholesterolemia found that diet plus colestipol therapy did not negatively impact plasma 25-hydroxycholecalciferol concentrations or calcium metabolism, though concentrations of vitamin A and vitamin E were significantly reduced after up to 2 years of therapy.<sup>15</sup><br><br>This suspected effect of bile acid sequestrants on vitamin D absorption could be the result of direct binding of the fat-soluble vitamin by the bile acid-binding resin, resin removal of bile acids that are necessary for fat-soluble vitamin absorption, or the impaired absorption could be secondary to drug-induced steatorrhea.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. <i>Med Toxicol</i>. 1987;2(1):10-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3547004\">[PubMed 3547004]</a></p>\n<p>2. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. <i>Gut</i>. 1975;16(2):93-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1168607\">[PubMed 1168607]</a></p>\n<p>3. Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D<sub>3</sub> and calcium. <i>Gut</i>. 1969;10(9):717-722. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4318526\">[PubMed 4318526]</a></p>\n<p>4. Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016.</p>\n<p>5. Welchol (colesevelam) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc.; June 2013.</p>\n<p>6. Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2010.</p>\n<p>7. Rocaltrol (calcitriol) [prescribing information. Parisppany, NJ: Validus Pharmaceuticals LLC; July 2009.</p>\n<p>8. One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc.; March 2010.</p>\n<p>9. Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals LLC; June 2016.</p>\n<p>10. Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. <i>Gastroenterology</i>. 1972;62(4):642-646. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5020877\">[PubMed 5020877]</a></p>\n<p>11. Compston JE, Horton LW. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. <i>Gastroenterology</i>. 1978;74(5 pt 1):900-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=640344\">[PubMed 640344]</a></p>\n<p>12. Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. <i>Dig Dis Sci</i>. 1985;30(5):477-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3987479\">[PubMed 3987479]</a></p>\n<p>13. Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. <i>Clin Ther</i>. 1990;12(5):427-430. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2125243\">[PubMed 2125243]</a></p>\n<p>14. Hoogwerf BJ, Hibbard DM, Hunninghake DB. Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. <i>J Lab Clin Med</i>. 1992;119(4):407-411. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1583392\">[PubMed 1583392]</a></p>\n<p>15. Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. <i>Pediatrics</i>. 1980;65(2):243-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7354970\">[PubMed 7354970]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5726":"<p><b>Title</b> Levothyroxine / Aluminum Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of levothyroxine are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aluminum Hydroxide may decrease the serum concentration of Levothyroxine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.</p> \n<p><b>Discussion</b> Prescribing information for levothyroxine lists aluminum-containing antacids as agents that may prevent absorption of T4 from the gastrointestinal tract, and recommends that such agents be administered at least 4 hours apart from levothyroxine.<sup>1</sup> Two case reports describe patients receiving stable levothyroxine therapy whose serum thyrotropin concentrations became elevated during treatment with aluminum hydroxide, and returned to normal values following aluminum hydroxide cessation.<sup>2,3</sup> Additionally, a clinical study of 5 patients receiving stable levothyroxine supplementation found that average thyrotropin concentrations increased from 2.62 mUnits/L at baseline to 7.19 mUnits/L following 2-4 weeks of aluminum hydroxide (564 mg orally 4 times daily).<sup>4</sup><br><br>The likely primary mechanism of this interaction is adsorption of levothyroxine to aluminum in the gastrointestinal tract. The formation of levothyroxine-aluminum complexes has not been confirmed in vivo, but dose-related adsorption has been demonstrated in two in vitro systems.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Synthroid (levothyroxine sodium). North Chicago, IL: Abbott Laboratories, 5/2009.</p>\n<p>2. Sperber AD and Liel Y, “Evidence for Interference With the Intestinal Absorption of Levothyroxine Sodium by Aluminum Hydroxide,” <i>Arch Intern Med</i>, 1992, 152(1):183-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1728914\">[PubMed 1728914]</a></p>\n<p>3. Mersebach H, Rasmussen AK, Kirkegaard L, et al, “Intestinal Adsorption of Levothyroxine by Antacids and Laxatives: Case Stories and In Vitro Experiments,” <i>Pharmacol Toxicol</i>, 1999, 84(3):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10193669\">[PubMed 10193669]</a></p>\n<p>4. Liel Y, Sperber AD and Shany S, “Nonspecific Intestinal Adsorption of Levothyroxine by Aluminum Hydroxide,” <i>Am J Med</i>, 1994, 97(4):363-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7942938\">[PubMed 7942938]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5727":"<p><b>Title</b> Loop Diuretics / Licorice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Licorice may enhance the hypokalemic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for development of hypokalemia in patients who consume large quantities of licorice during treatment with loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Furosemide prescribing information warns that hypokalemia may develop during treatment, particularly in patients receiving licorice in large amounts (among other circumstances).<sup>1</sup> Although the effects of combining loop diuretics with licorice have not been formally evaluated, both have been associated with development of clinically significant hypokalemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lasix (furosemide). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5728":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Licorice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Licorice may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for development of hypokalemia in patients who regularly consume licorice, particularly in large quantities, during treatment with thiazide diuretics.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, licorice (32 g daily) had no impact on plasma potassium concentrations, but licorice in combination with hydrochlorothiazide (25 mg orally daily) was associated with an average 0.32 mM decrease in plasma potassium.<sup>1</sup> Two patients discontinued combined treatment due to hypokalemia. Thiazide diuretics and licorice have both been associated with development of hypokalemia, so their combined use should be undertaken cautiously.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hukkanen J, Ukkola O and Savolainen MJ, “Effects of Low-Dose Liquorice Alone or in Combination With Hydrochlorothiazide on the Plasma Potassium in Healthy Volunteers,” <i>Blood Press</i>, 2009, 18(4):192-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19562574\">[PubMed 19562574]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5730":"<p><b>Title</b> Buprenorphine / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of Buprenorphine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of buprenorphine and metabolites were decreased to a modest but non-statistically-significant degree when nevirapine (200 mg daily x 15 days) was administered to 7 opioid-dependent, HIV-negative volunteers who were being maintained on buprenorphine/naloxone.<sup>1</sup> No opioid withdrawal symptoms were reported, further suggesting a non-significant interaction.<sup>1</sup><br><br>The proposed mechanism of action for this possible interaction is enhanced CYP3A4-mediated metabolism of buprenorphine due to CYP3A induction by nevirapine.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McCance-Katz EF, Moody DE, Morse GD, et al, “Lack of Clinically Significant Drug Interactions Between Nevirapine and Buprenorphine,” <i>Am J Addict</i>, 2010, 19(1):30-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20132119\">[PubMed 20132119]</a></p>\n<p>2. Prescribing information. Suboxone (buprenorphine and naloxone). Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc., 09/2010.</p>\n<p>3. Prescribing information. Viramune (nevirapine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5731":"<p><b>Title</b> Buprenorphine / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Efavirenz may decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical response to buprenorphine closely when adding or discontinuing concurrent efavirenz. Buprenorphine dose requirements may increase when efavirenz is initiated (or if efavirenz dose is increased), and/or signs/symptoms of opioid withdrawal may become apparent. Conversely, if efavirenz is discontinued (or if dose is decreased) in a patient previously maintained on the combination, signs/symptoms of excessive opioid response may be present and dose reductions may be required.</p> \n<p><b>Discussion</b> Both the buprenorphine AUC and norbuprenorphine (active metabolite) AUC were significantly reduced (by 50% and 71%, respectively) when efavirenz (600 mg daily x 15 days) was administered to 20 opioid-dependent volunteers who were being maintained on sublingual buprenorphine/naloxone (at doses of 16 mg/4 mg to 20 mg/5 mg daily).<sup>1</sup> Concentrations of both buprenorphine glucuronide and norbuprenorphine glucuronide were also substantially reduced by concurrent efavirenz. The total amount of buprenorphine, norbuprenorphine, and their glucuronide conjugates excreted in the urine (over 24 hrs) was also significantly decreased during concurrent efavirenz.<sup>2</sup> None of the study participants displayed any signs or symptoms of opioid withdrawal suggesting the observed pharmacokinetic changes may be of limited clinical significance.<br><br>The likely mechanism for this observed interaction is induction of the CYP3A4-mediated (and possibly UGT-mediated) metabolism of buprenorphine and norbuprenorphine by efavirenz<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McCance-Katz EF, Moody DE, Morse GD, et al, “Interactions between Buprenorphine And Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz And Delavirdine,” <i>Clin Infect Dis</i>, 2006, 43 Suppl 4:S224-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17109309\">[PubMed 17109309]</a></p>\n<p>2. Moody DE, Chang Y, Huang W, et al, “The In Vivo Response of Novel Buprenorphine Metabolites, M1 and M3, to Antiretroviral Inducers and Inhibitors of Buprenorphine Metabolism,” <i>Basic Clin Pharmacol Toxicol</i>, 2009, 104(3):211-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19500085\">[PubMed 19500085]</a></p>\n<p>3. Prescribing information. Suboxone (buprenorphine and naloxone). Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5732":"<p><b>Title</b> Indinavir / Bosentan</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Ritonavir): Refer to ritonavir-specific recommendations for bosentan dosing during treatment with boosted (indinavir/ritonavir) regimens.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Indinavir may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Indinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Initiate bosentan at, or adjust bosentan dose to, 62.5 mg once daily or every other day (based on tolerability) in patients who receive indinavir without ritonavir. Refer to ritonavir-specific recommendations for patients receiving ritonavir-boosted regimens. Additionally, monitor for possible reduced response to indinavir.</p> \n<p><b>Discussion</b> Indinavir prescribing information recommends that bosentan be started at or adjusted to 62.5 mg once daily or every other day (based on tolerability) in patients who receive indinavir, due to a risk of elevated bosentan concentrations.<sup>1</sup><br><br>Additionally, one published case report describes a patient whose serum indinavir concentrations decreased to undetectable levels (less than 0.05 mg/L, compared to 0.11 mg/L on the same regimen months earlier) following addition of bosentan (62.5 mg orally twice daily, then 125 mg twice daily).<sup>2</sup><br><br>Interactions between these agents likely occur via at least two primary mechanisms: indinavir inhibition of CYP3A4 mediated bosentan metabolism; and bosentan induction of CYP3A4 mediated indinavir metabolism. The net impact of these two agents on CYP3A4 function has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., November 2010.</p>\n<p>2. Beau-Salinas F, Garot D, Le Guellec C, et al, “Possible Reduction in Indinavir Serum Concentrations by Bosentan,” <i>Ther Drug Monit</i>, 2005, 27(6):822-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16306862\">[PubMed 16306862]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5733":"<p><b>Title</b> Nelfinavir / Bosentan</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nelfinavir may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Nelfinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Initiate bosentan dose at, or adjust bosentan dose to, 62.5 mg once daily or every other day (based on tolerability) in patients who receive nelfinavir. Additionally, monitor for possible reduced clinical response to nelfinavir.</p> \n<p><b>Discussion</b> Nelfinavir prescribing information recommends that bosentan be started at or adjusted to 62.5 mg once daily or every other day (based on tolerability) in patients who receive nelfinavir, due to a risk of elevated bosentan concentrations.<sup>1</sup><br><br>The likely primary mechanism of this interaction is nelfinavir inhibition of CYP3A4 mediated bosentan metabolism. Additionally, bosentan could theoretically reduce nelfinavir concentrations via induction of CYP3A4 mediated nelfinavir metabolism, although clinical data verifying such an effect are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5734":"<p><b>Title</b> Vitamin D Analogs / Orlistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Only orally administered vitamin D analogs are subject to this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat.</p>\n<div>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcitriol (Systemic), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol<br><b>Exceptions</b> Calcipotriene, Calcitriol (Topical), Tacalcitol</p>\n</div> \n<p><b>Discussion</b> Orlistat prescribing information describes reduced absorption of supplemental beta carotene (average 30% decrease) and vitamin E (average 60% decrease) associated with its concomitant use.<sup>1</sup> The influence of orlistat on the absorption of other fat soluble vitamins including diet-derived vitamin K or supplemental vitamin A and D is less clear; however, data in the prescribing information show that, of patients with normal baseline vitamin D concentrations, nearly twice as many orlistat-treated patients display low vitamin D concentrations at two or more consecutive visits as compared to placebo-treated patients (among both adult and pediatric patients).<sup>1</sup> While no human studies or case reports have documented an interaction between paricalcitol and orlistat, paricalcitol prescribing information cautions that drugs capable of impairing fat-soluble vitamin absorption may limit the absorption of paricalcitol.<sup>2</sup> As orlistat inhibits gastric and pancreatic lipase, it would seem prudent to anticipate a similar effect on the absorption of other vitamin D analogs as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenical (orlistat). South San Francisco, CA: Genentech USA, Inc., May 2010.</p>\n<p>2. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5735":"<p><b>Title</b> Cardiac Glycosides / Vitamin D Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum calcium concentrations closely and watch for signs and symptoms of cardiac glycoside toxicity in patients receiving a vitamin D analog and a cardiac glycoside together. It is in the setting of hypercalcemia that the conduction effects of cardiac glycosides are enhanced.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcipotriene, Calcitriol (Systemic), Calcitriol (Topical), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol, Tacalcitol</p>\n</div> \n<p><b>Discussion</b> Existing data show that hypercalcemia (an appreciable risk of vitamin D analog therapy) and cardiac glycosides, such as digoxin, have similar effects on cardiac conduction.<sup>1,2</sup> Consequently, clinically significant adverse effects on cardiac conduction can occur even at therapeutic concentrations of cardiac glycosides in the setting of hypercalcemia.<sup>1</sup> Similarly, cardiac glycosides can exacerbate the negative cardiovascular effects of hypercalcemia. A case report describing an elderly patient who experienced a clinically significant bradyarrhythmia attributed to hypercalcemia (total calcium = 3.0 mmol/L; normal: 2.2-2.5 mmol/L) and digoxin therapy (digoxin concentration = 1.5 ng/mL; normal/therapeutic: 0.5-2.0 ng/mL) exemplifies this risk.<sup>1</sup><br><br>The mechanism by which hypercalcemia and cardiac glycosides augment one another's effects on conduction involves both the Na<sup>+</sup>/K<sup>+</sup>-ATPase and the Ca<sup>2+</sup>/Na<sup>+</sup>-antiporter. Cardiac glycosides are known to inhibit Na<sup>+</sup>/K<sup>+</sup>-ATPase,<sup>2</sup> increasing intracellular sodium concentrations. This increase in intracellular sodium inhibits action of the Ca<sup>2+</sup>/Na<sup>+</sup>-antiporter, which normally transports sodium into the cell as it transports calcium out of the cell. The net effect of inhibiting this antiporter, then, is increased intracellular calcium.<sup>1</sup> Both the cardiac glycosides and excess calcium (i.e., hypercalcemia) decrease the cardiac excitation threshold, shorten the effective refractory period, and increase the refractoriness of the AV node.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vella A, Gerber TC, Hayes DL, et al, “Digoxin, Hypercalcemia, and Cardiac Conduction,” <i>Postgrad Med J</i>, 1999, 75:554-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616693\">[PubMed 10616693]</a> </p>\n<p>2. Kelly RA, Smith TW, “Pharmacological Treatment of Heart Failure,” In: Hardman JG, Limbird LE, Molinoff PB, et al, eds, <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>, 9th ed. New York, NY: McGraw-Hill, 1996:809-38.]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5742":"<p><b>Title</b> Vitamin K Antagonists / Chloramphenicol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol (Systemic) may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of vitamin K antagonists (e.g., prothrombin time/INR, and signs and symptoms of bleeding) with initiation/dose increase of chloramphenicol. Dosage reductions of the vitamin K antagonist may be necessary. If chloramphenicol is discontinued or dose decreased, monitor for decreased effects of the vitamin K antagonist.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A single case report describes an 83 year old female stable on warfarin therapy whose INR rose to 8.92 following administration of a chloramphenicol-containing ophthalmic preparation.<sup>1</sup> The half-life of dicumarol (no longer available in the U.S. and Canada) in 4 patients was increased an average of 3-fold following 5-8 days of chloramphenicol therapy (2 g/day).<sup>2</sup> Case reports and/or studies regarding chloramphenicol and acenocoumarol are lacking. Warfarin prescribing information and acenocoumarol product monograph both include chloramphenicol as a potentially interacting drug.<sup>3,4</sup><br><br>Precise mechanism(s) for the observed interactions are not clear. Authors of the described case report<sup>1</sup> acknowledge that other patient factors (e.g., hepatic congestion as a result of CHF) may have contributed to the observed increase in INR. In an animal study, chloramphenicol decreased the plasma clearance of both R- and S-warfarin but had no apparent effect on the serum protein binding of warfarin.<sup>5</sup> Chloramphenicol may inhibit the hepatic metabolism of warfarin<sup>1,6</sup> and of acenocoumarol. In vitro, chloramphenicol failed to inhibit CYP2C9 but inhibited CYP2C19 and 3A4.<sup>7</sup> S-warfarin (more potent enantiomer) and S-acenocoumarol (less potent enantiomer) undergo hepatic metabolism primarily by CYP2C9, whereas the R-enantiomers undergo metabolism by multiple other CYP enzymes, including 3A4 (warfarin) and 2C19 (warfarin, acenocoumarol).<sup>3,8</sup><br><br>Other possible mechanisms might include chloramphenicol-mediated inhibition of the hepatic production of prothrombin,<sup>9</sup> although this effect was not observed in an animal study,<sup>5</sup> or reduction in intestinal flora, which are thought to synthesize vitamin K.<sup>10,11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Leone R, Ghiotto E, Conforti A, et al, “Potential Interaction Between Warfarin and Ocular Chloramphenicol,” <i>Ann Pharmacother</i>, 1999, 33(1):114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9972397\">[PubMed 9972397]</a></p>\n<p>2. Christensen LK and Skovsted L, “Inhibition of Drug Metabolism by Chloramphenicol,” <i>Lancet</i>, 1969, ii:1397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4188280\">[PubMed 4188280]</a></p>\n<p>3. Prescribing information. Coumadin (warfarin). Princeton, NJ: Bristol-Myers Squibb, January 2010.</p>\n<p>4. Product monograph. Sintrom (acenocoumarol). Montreal, Quebec: Paladin Labs Inc., May 2009.</p>\n<p>5. Yacobi A, Lai CM, and Levy G, “Pharmacokinetic and Pharmacodynamic Studies of Acute Interaction Between Warfarin Enantiomers and Chloramphenicol in Rats,” <i>J Pharmacol Exp Ther</i>, 1984, 231(1):80-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6491977\">[PubMed 6491977]</a></p>\n<p>6. Michalets EL, “Update: Clinically Significant Cytochrome P-450 Drug Interactions,” <i>Pharmacotherapy</i>, 1998, 18(1):84-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9469685\">[PubMed 9469685]</a></p>\n<p>7. Park JY, Kim KA, and Kim SL, “Chloramphenicol is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes,” <i>Antimicrob Agents Chemother</i>, 2003, 47(11):3464-9. [PubMed14576103]</p>\n<p>8. Thijssen HH, Flinois JP, and Beaune PH, “Cytochrome P4502C9 is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes,” <i>Drug Metab Dispos</i>, 2000, 28(11): 1284-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11038154\">[PubMed 11038154]</a></p>\n<p>9. Klippel AP and Pitsinger B, “Hypoprothrombinaemia Secondary to Antibiotic Therapy and Manifested by Massive Gastrointestinal Haemorrhage,” <i>Arch Surg</i>, 1968, 96:266. [PubMed 5317509]</p>\n<p>10. Udall JA, “Human Sources and Absorption of Vitamin K in Relation to Anticoagulation Stability,” <i>JAMA</i>, 1965, 194(2): 127-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5897315\">[PubMed 5897315]</a></p>\n<p>11. Conly J and Stein K, “Reduction of Vitamin K2 Concentrations in Human Liver Associated with the Use of Broad Spectrum Antimicrobials,” <i>Clin Invest Med</i>, 1994, 17(6): 531-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7895417\">[PubMed 7895417]</a></p>\n<p>12. O'Reilly RA and Aggeler PM, “Determinants of the Response to Oral Anticoagulant Drugs in Man,” <i>Pharmacol Rev</i>, 1970, 22(1): 35-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4918964\">[PubMed 4918964]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5743":"<p><b>Title</b> Corticosteroids (Orally Inhaled) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended. Use caution when considering concurrent use of a strong CYP3A4 inhibitor with any inhaled corticosteroid. Monitor patients extra closely for signs and symptoms of adrenal suppression if such a combination is used. The risk for a significant interaction may be lower with inhaled beclomethasone, ciclesonide, flunisolide, or triamcinolone.</p>\n<div>\n <p><b>Corticosteroids (Orally Inhaled) Interacting Members</b> Budesonide (Oral Inhalation), Ciclesonide (Oral Inhalation), Flunisolide (Oral Inhalation), Fluticasone (Oral Inhalation)*, Mometasone (Oral Inhalation)<br><b>Exceptions</b> Beclomethasone (Oral Inhalation), Triamcinolone (Systemic)</p>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole*, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir*, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Increased systemic exposure to inhaled budesonide and fluticasone propionate, and a corresponding risk of development of Cushing's syndrome, have been reported in patients treated with the strong CYP3A4 inhibitors itraconazole or ritonavir.<sup>1,2,3,4,5,6,7</sup> The fluticasone AUC increased nearly 2-fold when orally inhaled fluticasone propionate (1000 mcg) was given with the strong CYP3A4 inhibitor ketoconazole (200 mg/day) in a study of 8 healthy volunteers.<sup>7</sup> Plasma cortisol AUC decreased by an average of 45% with the combination. Of note, a study with aqueous nasally inhaled fluticasone propionate found that fluticasone AUC increased more than 100-fold when nasally inhaled fluticasone propionate (200 mcg/day) was given with the strong CYP3A4 inhibitor ritonavir (100 mg twice/day) for 7 days (n=18 healthy volunteers).<sup>7</sup> In these subjects, plasma cortisol AUC was reduced by an average of 86%. Consequently, fluticasone propionate prescribing information specifically states that use in combination with strong CYP3A4 inhibitors is not recommended, while the budesonide prescribing information states that use with a strong CYP3A4 inhibitor should be done cautiously.<sup>7,8</sup><br><br>Mometasone plasma concentrations increased by as much as 2-fold when used with ketoconazole.<sup>9</sup> Similarly, the fluticasone AUC increased by an average of 36% when fluticasone furoate/vilanterol (200 mcg/25 mcg once/day x 7 days) was given with ketoconazole (400 mg/day x 11 days).<sup>10</sup> Average plasma cortisol was 27% lower with use of the combination. Prescribing information for both fluticasone furoate and mometasone recommends cautious use with strong CYP3A4 inhibitors.<sup>9,11</sup><br><br>The AUC of des-ciclesonide, the active metabolite of ciclesonide, was an average of 3.6-fold higher when orally inhaled ciclesonide was given with ketoconazole.<sup>12</sup> Despite this apparent interaction, the ciclesonide prescribing information does not specifically warn or caution about use with strong CYP3A4 inhibitors.<br><br>Inhaled beclomethasone, flunisolide, and triamcinolone are less likely to be affected by CYP3A4 inhibition due to slower rate of elimination by CYP3A4 and low receptor binding affinity and the prescribing information for each does not specifically caution about CYP3A4 interactions.<sup>13,14,15,16,17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Raaska K, Niemi M, Neuvonen M, et al, “Plasma Concentrations of Inhaled Budesonide and Its Effects on Plasma Cortisol Are Increased by the Cytochrome P4503A4 Inhibitor Itraconazole,” <i>Clin Pharmacol Ther</i>, 2002, 72(4):362-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386638\">[PubMed 12386638]</a></p>\n<p>2. Bolland MJ, Bagg W, Thomas MG, et al, “Cushing's Syndrome Due to Interaction Between Inhaled Corticosteroids and Itraconazole,” <i>Ann Pharmacother</i>, 2004, 38(1):46-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742792\">[PubMed 14742792]</a></p>\n<p>3. De Wachter E, Vanbesien J, De Schutter I, et al, “Rapidly Developing Cushing Syndrome in a 4-Year-Old Patient During Combined Treatment With Itraconazole and Inhaled Budesonide,” <i>Eur J Pediatr</i>, 2003, 162(7-8):488-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12719971\">[PubMed 12719971]</a></p>\n<p>4. Workman C, Hayes J, Kelly M, et al, “Iatrogenic Cushing's Disease From Ritonavir Inhibition of Fluticasone Metabolism,” An abstract Presented at the Meeting of the Australasian Society of HIV Medicine, Melbourne, Australia, October 5, 2001.</p>\n<p>5. Clevenbergh P, Corcostegui M, Gerard D, et al, “Iatrogenic Cushing's Syndrome in an HIV-Infected Patient Treated With Inhaled Corticosteroids (Fluticasone Propionate) and Low Dose Ritonavir Enhanced PI Containing Regimen,” <i>J Infect</i>, 2002, 44(3):194-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12099750\">[PubMed 12099750]</a></p>\n<p>6. Rouanet I, Peyriere H, Mauboussin JM, et al, “Cushing's Syndrome in a Patient Treated by Ritonavir/Lopinavir and Inhaled Fluticasone,” <i>HIV Med</i>, 2003, 4(2):149-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12702137\">[PubMed 12702137]</a></p>\n<p>7. Prescribing information. Flovent HFA (fluticasone propionate). Research Triangle Park, NC: GlaxoSmithKline, 01/2012.</p>\n<p>8. Prescribing information. Pulmicort (budesonide). Wilmington, DE: AstraZeneca LP, 07/2010.</p>\n<p>9. Prescribing information. Dulera (mometasone/formoterol). Whitehouse Station, NJ: Merck &amp; Co., Inc., June 2010.</p>\n<p>10. Kempsford R, Allen A, Bal J, et al, “The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Inhaled Fluticasone Furoate and Vilanterol Trifenatate in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2013, 75(6):1478-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23116485\">[PubMed 23116485]</a></p>\n<p>11. Prescribing information. Breo Ellipta (fluticasone furoate/vilanterol). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p>12. Prescribing information. Alvesco (ciclesonide). Marlborough, MA: Sunovion Pharmaceuticals Inc., December 2012.</p>\n<p>13. Moore CD, Roberts JK, Orton CR, et al, “Metabolic Pathways of Inhaled Glucocorticoids by the CYP3A Enzymes,” <i>Drug Metab Dispos</i>, 2013, 41(2):379-89. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23143891\">[PubMed 23143891]</a></p>\n<p>14. Kelly HW, “Comparison of Inhaled Corticosteroids: An Update,” <i>Ann Pharmacother</i>, 2009, 43(3):519-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19261959\">[PubMed 19261959]</a></p>\n<p>15. Prescribing information. Qvar (beclomethasone). Horsham, PA: Teva Respiratory, LLC, July 2012.</p>\n<p>16. Prescribing information. Aerospan HFA (flunisolide). St. Louis, MO: Forest Laboratories, Inc., 1/2006.</p>\n<p>17. Prescribing information. Azmacort (triamcinolone). Cranbury, NJ: Kos Pharmaceuticals, Inc., 03/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5744":"<p><b>Title</b> Vitamin D Analogs / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor both serum calcium concentrations and response to vitamin D analogs closely in all patients receiving a vitamin D analog and a thiazide diuretic.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcipotriene, Calcitriol (Systemic), Calcitriol (Topical), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol, Tacalcitol</p>\n</div> \n<p><b>Discussion</b> The product labeling for both ergocalciferol and calcitriol recommend caution with concomitant use of a thiazide diuretic due to the risk of hypercalcemia.<sup>1,2</sup> Studies regarding the effect of thiazide diuretics in combination with either of these agents are relatively lacking. One small study of 6 healthy volunteers fed a low-calcium diet found that those receiving calcitriol differed very little in their response to thiazides from those not receiving calcitriol with regard to measures of calcium balance and vitamin D/parathyroid hormone systems.<sup>3</sup> Thiazides have been shown to decrease urinary calcium excretion in both healthy volunteers<sup>3</sup> and children on long-term calcitriol treatment.<sup>4</sup> However, no change in urinary calcium excretion was reported in patients with hypoparathyroidism being treated with vitamin D,<sup>5</sup> leading the study authors to conclude that parathyroid hormone is required for thiazides to have their anti-calciuric effects. This ability to diminish urinary calcium excretion has stimulated interest in using thiazide diuretics with calcitriol to prevent/treat hypocalcemia in certain patients, and one such study reported less hypocalcemia following thyroidectomy in patients receiving calcitriol plus hydrochlorothiazide (n=22) than those receiving placebo (n=20) (4.5% vs. 50%).<sup>6</sup><br><br>Studies examining the effects of thiazide diuretics on calcium and vitamin D metabolism without concurrent calcitriol treatment have reported variable findings. While thiazides have been shown to decrease urinary calcium excretion in healthy volunteers<sup>7,8,9</sup> and patients with idiopathic hypercalciuria,<sup>10</sup> the net effect on calcium concentrations has ranged from increased concentrations<sup>5,7</sup> to no change<sup>8,10</sup> to decreased concentrations.<sup>6,11,12</sup> The reported effects of thiazides on concentrations of endogenous calcitriol and various vitamin D metabolites have been similarly mixed.<sup>7,8,9,10,11,12</sup><br><br>As hypercalcemia is a potential adverse event associated with vitamin D analog therapy, it would seem prudent to closely monitor serum calcium concentrations in patients receiving concomitant thiazide diuretic therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, November 2009. </p>\n<p>2. Prescribing information Rocaltrol (calcitriol). Parsippany, NJ: Validus Pharmaceuticals LLC, July 2009.</p>\n<p>3. Lemann J, Jr., Gray RW, Maierhofer WJ, et al., “Hydrochlorothiazide Inhibits Bone Resorption in Men Despite Experimentally Elevated Serum 1,25-Dihydroxyvitamin D Concentrations,” <i>Kidney Int</i>, 1985, 28:951-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3003445\">[PubMed 3003445]</a></p>\n<p>4. Santos F, Smith MJ,Chan JC, “Hypercalciuria Associated with Long-Term Administration of Calcitriol (1,25-Dihydroxyvitamin D3). Action of Hydrochlorothiazide,” <i>Am J Dis Child</i>, 1986, 140:139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3753816\">[PubMed 3753816]</a></p>\n<p>5. Brickman AS, Massry SG,Coburn JW, “Changes in Serum and Urinary Calcium During Treatment with Hydrochlorothiazide: Studies on Mechanisms,” <i>J Clin Invest</i>, 1972, 51:945-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552338\">[PubMed 4552338]</a></p>\n<p>6. Testa A, Fant V, De Rosa A, et al., “Calcitriol Plus Hydrochlorothiazide Prevents Transient Post-Thyroidectomy Hypocalcemia,” <i>Horm Metab Res</i>, 2006, 38:821-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17163358\">[PubMed 17163358]</a></p>\n<p>7. Krause U, Zielke A, Schmidt-Gayk H, et al., “Direct Tubular Effect on Calcium Retention by Hydrochlorothiazide,” <i>J Endocrinol Invest</i>, 1989, 12:531-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2592738\">[PubMed 2592738]</a></p>\n<p>8. Rejnmark L, Vestergaard P, Heickendorff L, et al., “Effects of Thiazide- and Loop-Diuretics, Alone or in Combination, on Calcitropic Hormones and Biochemical Bone Markers: A Randomized Controlled Study,” <i>J Intern Med</i>, 2001, 250:144-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11489064\">[PubMed 11489064]</a></p>\n<p>9. Riis B,Christiansen C, “Actions of Thiazide on Vitamin D Metabolism: A Controlled Therapeutic Trial in Normal Women Early in the Postmenopause,” <i>Metabolism</i>, 1985, 34:421-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3887100\">[PubMed 3887100]</a></p>\n<p>10. Coe FL, Parks JH, Bushinsky DA, et al., “Chlorthalidone Promotes Mineral Retention in Patients with Idiopathic Hypercalciuria,” <i>Kidney Int</i>, 1988, 33:1140-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3404813\">[PubMed 3404813]</a></p>\n<p>11. Nowack R, Hofner MC, Reichel H, et al., “Subacute Effects of Thiazide Administration on Renal Hemodynamics and Calcium Metabolism,” <i>Clin Investig</i>, 1992, 70:686-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1392446\">[PubMed 1392446]</a></p>\n<p>12. Rejnmark L, Vestergaard P, Pedersen AR, et al., “Dose-Effect Relations of Loop- and Thiazide-Diuretics on Calcium Homeostasis: A Randomized, Double-Blinded Latin-Square Multiple Cross-over Study in Postmenopausal Osteopenic Women,” <i>Eur J Clin Invest</i>, 2003, 33:41-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12492451\">[PubMed 12492451]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5745":"<p><b>Title</b> Amantadine / Sulfamethoxazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfamethoxazole may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of myoclonus, delirium, or other neurological complications (e.g., abnormal gait) during concomitant administration of amantadine and sulfamethoxazole. If symptoms develop, discontinuation or dose reduction of one or both agents may be necessary. Patients with impaired renal function may be at greater risk for these adverse effects.</p> \n<p><b>Discussion</b> An 84 year old man receiving amantadine (100 mg twice daily for 2 years) for Parkinson’s disease developed mental confusion, cogwheel rigidity, resting tremor, and combativeness 72 hours after the addition of trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily) to treat bronchitis.<sup>1</sup> Within 24 hours of discontinuing both agents, the patient’s mental status returned to normal. Similar adverse events have been reported with use of the related compound memantine in conjunction with TMP/SMX and TMP alone.<sup>2</sup> <br><br>The mechanism by which SMX may increase the risk of amantadine adverse reactions is unknown. The cases described may be more likely a result of the TMP component given a number of plausible mechanistic explanations (e.g., competition for organic cation transporter-2 mediated transport, additive myoclonus producing effects, etc).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Speeg KV, Leighton JA, and Maldonoado AL, “Case Report: Toxic Delirium in a Patient Taking Amantadine and Trimethoprim-Sulfamethoxazole,” Am J Med Sci, 1989, 298:410-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2596498\">[PubMed 2596498]</a></p>\n<p>2. Prescribing Information. Bactrim (sulfamethoxazole/trimethoprim). Philadelphia, PA: Mutual Pharmaceutical Company, Inc., March 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5747":"<p><b>Title</b> Vaccines (Live) / Belimumab</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Belimumab may enhance the adverse/toxic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of any live vaccines within 30 days prior to or concurrent with administration of belimumab.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but due to belimumab's mechanism of action, which includes inhibition of B cell survival and decreased differentiation into immunoglobulin-producing plasma cells, the belimumab prescribing information recommends avoiding the use of live vaccines within 30 days prior to administration or concurrently with belimumab.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Benlysta (belimumab). Rockville, MD: Human Genome Sciences, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5748":"<p><b>Title</b> Vaccines (Inactivated) / Belimumab</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Belimumab may diminish the therapeutic effect of Vaccines (Inactivated). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy. Monitor clinical responsiveness to any vaccines given during belimumab therapy, as possible.</p>\n<div>\n <p><b>Vaccines (Inactivated) Interacting Members</b> Anthrax Vaccine Adsorbed, Diphtheria and Tetanus Toxoids, Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated), and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine, Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), and Poliovirus (Inactivated) Vaccine, Haemophilus b Conjugate Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine (Recombinant [Adjuvanted]), Hepatitis B Vaccine (Recombinant), Influenza A Virus Vaccine (H5N1), Influenza Virus Vaccine (Inactivated), Japanese Encephalitis Virus Vaccine (Inactivated), Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine, Meningococcal Group B Vaccine, Meningococcal Group C-CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide (Groups C and Y) and Haemophilus b Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Group C Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine (Groups A / C / Y and W-135), Papillomavirus (9-Valent) Vaccine (Human, Recombinant), Papillomavirus (Types 16, 18) Vaccine (Human, Recombinant), Papillomavirus (Types 6, 11, 16, 18) Vaccine (Human, Recombinant), Pneumococcal Conjugate Vaccine (10-Valent), Pneumococcal Conjugate Vaccine (13-Valent), Pneumococcal Conjugate Vaccine (7-Valent), Pneumococcal Polysaccharide Vaccine (23-Valent), Poliovirus Vaccine (Inactivated), Q Fever Vaccine, Rabies Vaccine, Tetanus Toxoid (Adsorbed), Tick-Borne Encephalitis Virus Vaccine (Inactivated), Travelers' Diarrhea and Cholera Vaccine, Typhoid and Hepatitis A Vaccine, Zoster Vaccine (Recombinant)</p>\n</div> \n<p><b>Discussion</b> Specific data regarding this interaction are not available, but due to belimumab's mechanism of action, which includes inhibition of B cell survival and decreased differentiation into immunoglobulin-producing plasma cells, the belimumab prescribing information cautions that belimumab may interfere with the response to vaccines.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Benlysta</i> (belimumab) [prescribing information]. Rockville, MD: Human Genome Sciences, Inc.; March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5749":"<p><b>Title</b> Cyclophosphamide / Belimumab</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Intravenous cyclophosphamide is specified in the prescribing information describing this possible interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Belimumab may enhance the adverse/toxic effect of Cyclophosphamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of IV cyclophosphamide with belimumab is not recommended.</p> \n<p><b>Discussion</b> According to the belimumab prescribing information, concurrent use of IV cyclophosphamide is not recommended.<sup>1</sup> Specific data on the safety/risks of this combination are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Benlysta (belimumab). Rockville, MD: Human Genome Sciences, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5750":"<p><b>Title</b> Vitamin K Antagonists / Cranberry</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cranberry may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Consider monitoring of cranberry ingestion among patients taking warfarin or acenocoumarol and possibly increased monitoring for increased INR/effects of the vitamin K antagonist in patients who report excessive cranberry ingestion or recent changes in cranberry consumption. Though the evidence regarding this possible interaction is conflicting, it seems reasonable to counsel patients receiving warfarin or acenocoumarol to report their consumption of cranberry juice and to avoid substantial changes in cranberry juice ingestion.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe increased INR and/or associated bleeding in previously stable patients being treated with warfarin within a few days and up to 6 weeks after beginning regular consumption of cranberry juice or cranberry sauce.<sup>1,2,3,4,5,6,7</sup> One study in 12 healthy volunteers found that the INR-time curve (following a single warfarin 25 mg dose) increased by 30% after 2 weeks of cranberry juice.<sup>8</sup> Conversely, at least three other controlled studies have concluded that cranberry juice had no significant impact on INR and/or warfarin serum concentrations.<sup>9,10,11</sup><br><br>In one study of 10 healthy volunteers, the average response to warfarin (10 mg x1) was not significantly different after cranberry juice (200 mL TID x 7 days).<sup>9</sup> A study of 7 patients with atrial fibrillation on stable warfarin doses also found no significant difference in average INR after cranberry juice administration (250 mL juice daily x 7 days).<sup>10</sup> Similarly, a study of 30 patients stabilized on warfarin therapy found no significant differences in warfarin plasma concentrations after 2 weeks of cranberry juice administration (240 mL daily).<sup>11</sup> An equal number of patients in the cranberry juice and placebo arms experienced mild elevations of INR during the study, and the only difference in average INRs between groups was a small (but statistically significant) increase in the cranberry juice group on day 12, which the authors concluded was to unlikely to be of clinical significance.<sup>11</sup><br><br>A clear explanation for the discrepant findings between these controlled studies and the conclusions of the many published case reports has not been provided, though differences in cranberry juice dose/duration, patient characteristics, etc., could be at least partially responsible. A recent review of 15 case report describing a possible warfarin-cranberry interaction and 7 clinical studies concluded that most of the current warnings concerning this possible interaction are based on weak evidence and are potentially misleading.<sup>12</sup><br><br>A mechanism for this potential interaction is unclear. Cranberries contain compounds that have been associated with altered activity of various cytochromes P450 (CYP).<sup>13</sup> Since S-warfarin (most potent enantiomer) is metabolized primarily via CYP2C9, inhibition of this enzyme and/or the several CYPs responsible for R-warfarin metabolism could account for the effects observed in the published cases. However, one study of 14 healthy volunteers found that cranberry juice did not significantly impact CYP2C9 activity (assessed using flurbiprofen clearance).<sup>14</sup> R-acenocoumarol (most potent enantiomer) is metabolized primarily via CYP2C9,<sup>15</sup> however, published case reports and/or studies of cranberry intake in patients receiving acenocoumarol are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hamann GL, Campbell JD, George CM, “Warfarin-Cranberry Juice Interaction,” <i>Ann Pharmacother</i>, 2011, 45(3): e17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21364039\">[PubMed 21364039]</a> </p>\n<p>2. Grant P, “Warfarin and Cranberry Juice: An Interaction?,” <i>J Heart Valve Dis</i>, 2004, 13(1):25-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14765835\">[PubMed 14765835]</a></p>\n<p>3. Suvarna R, Pirmohamed M, and Henderson L, “Possible Interaction Between Warfarin and Cranberry Juice,” <i>BMJ</i>, 2003, 20;327(7429):1454. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14684645\">[PubMed 14684645]</a></p>\n<p>4. Paeng CH, Sprague M, Jackevicius CA, “Interaction Between Warfarin and Cranberry Juice,” <i>Clin Ther</i>, 2007, 29(8):1730-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17919554\">[PubMed 17919554]</a></p>\n<p>5. Rindone JP, Murphy TW, “Warfarin-Cranberry Juice Interaction Resulting in Profound Hypoprothrombinemia and Bleeding,” <i>Am J Ther</i>, 2006, 13(3):283-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772772\">[PubMed 16772772]</a></p>\n<p>6. Griffiths AP, Beddall A, Pegler S, “Fatal Haemopericardium and Gastrointestinal Haemorrhage Due to Possible Interaction of Cranberry Juice with Warfarin,” <i>J R Soc Promot Health</i>, 2008, 128(6):324-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19058474\">[PubMed 19058474]</a></p>\n<p>7. Mergenhagen KA, Sherman O, “Elevated International Normalized Ratio After Concurrent Ingestion of Cranberry Sauce and Warfarin,” <i>Am J Health Syst Pharm</i>, 2008, 65(22):2113-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18997138\">[PubMed 18997138]</a></p>\n<p>8. Mohammed Abdul MI, Jiang X, Williams KM, et al, “Pharmacodynamic Interaction of Warfarin with Cranberry but Not with Garlic in Healthy Subjects,” <i>Br J Pharmacol</i>, 2008, 154(8):1691-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18516070\">[PubMed 18516070]</a></p>\n<p>9. Lilja JJ, Backman JT, Neuvonen PJ, “Effects of Daily Ingestion of Cranberry Juice on the Pharmacokinetics of Warfarin, Tizanidine, and Midazolam--Probes of CYP2C9, CYP1A2, and CYP3A4,” <i>Clin Pharmacol Ther</i>, 2007, 81(6):833-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17392729\">[PubMed 17392729]</a></p>\n<p>10. Li Z, Seeram NP, Carpenter CL, et al, “Cranberry Does Not Affect Prothrombin Time in Male Subjects on Warfarin,” <i>J Am Diet Assoc</i>, 2006, 106(12):2057-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17126638\">[PubMed 17126638]</a></p>\n<p>11. Ansell J, McDonough M, Zhao Y, et al, “The Absence of an Interaction Between Warfarin and Cranberry Juice: A Randomized, Double-Blind Trial,” <i>J Clin Pharmacol</i>, 2009, 49(7):824-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19553405\">[PubMed 19553405]</a></p>\n<p>12. Zikria J, Goldman R, Ansell J, “Cranberry Juice and Warfarin: When Bad Publicity Trumps Science,” <i>Am J Med</i>, 2010, 123(5):384-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20399311\">[PubMed 20399311]</a></p>\n<p>13. Hodek P, Trefil P, and Stiborova M, “Flavonoids-Potent and Versatile Biologically Active Compounds Interacting With Cytochromes P450,” <i>Chem Biol Interact</i>, 2002, 22;139(1):1-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11803026\">[PubMed 11803026]</a></p>\n<p>14. Greenblatt DJ, von Moltke LL, Perloff ES, et al, “Interaction of Flurbiprofen with Cranberry Juice, Grape Juice, Tea, and Fluconazole: In Vitro and Clinical Studies,” <i>Clin Pharmacol Ther</i>, 2006, 79(1):125-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16413247\">[PubMed 16413247]</a></p>\n<p>15. Thijssen HH, Flinois JP, Beaune PH, “Cytochrome P4502C9 is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes,” <i>Drug Metab Dispos</i>, 2000, 28(11):1284-90. [PubMed11038154]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5751":"<p><b>Title</b> Vitamin K Antagonists / TraMADol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> TraMADol may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for INR changes, particularly elevations, when tramadol is given to patients receiving vitamin K antagonists.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Three case reports describe warfarin treated patients who experienced international normalized ratio (INR) elevations following initiation of tramadol.<sup>1,2,3</sup> One of the cases was associated with blood blisters on the feet,<sup>1</sup> and another with upper arm ecchymosis.<sup>2</sup> Only one of the patients had recently changed any other medications, discontinuing methocarbamol at an undisclosed time prior to tramadol initiation.<sup>3</sup><br><br>In addition to these case reports, an analysis of a Swedish adverse events reporting system uncovered 17 reported cases of a possible warfarin-tramadol interaction leading to elevated INR, with bleeding complications reported in 6 cases.<sup>4</sup> U.S. and Canadian product monographs for tramadol also highlight rare post-marketing reports of altered warfarin response, including elevated INR.<sup>5,6</sup><br><br>The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Scher ML, Huntington NH and Vitillo JA, “Potential Interaction Between Tramadol and Warfarin,” <i>Ann Pharmacother</i>, 1997, 31(5):646-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9161668\">[PubMed 9161668]</a></p>\n<p>2. Sabbe JR, Sims PJ and Sims MH, “Tramadol-Warfarin Interaction,” <i>Pharmacotherapy</i>, 1998, 18(4):871-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9692666\">[PubMed 9692666]</a></p>\n<p>3. Dumo PA and Kielbasa LA, “Successful Anticoagulation and Continuation of Tramadol Therapy in the Setting of a Tramadol-Warfarin Interaction,” <i>Pharmacotherapy</i>, 2006, 26(11):1654-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17064212\">[PubMed 17064212]</a></p>\n<p>4. Hedenmalm K, Lindh JD, Sawe J, et al, “Increased Liability of Tramadol-Warfarin Interaction in Individuals With Mutations in the Cytochrome P450 2D6 Gene,” <i>Eur J Clin Pharmacol</i>, 2004, 60(5):369-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197521\">[PubMed 15197521]</a></p>\n<p>5. Prescribing information. Ultram (tramadol). Raritan, New Jersey: PriCara, September 2009.</p>\n<p>6. Product monograph. Ultram (tramadol). Toronto, ON: Janssen-Ortho Inc., July 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5752":"<p><b>Title</b> Vitamin K Antagonists / Ethacrynic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ethacrynic Acid may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider more frequent monitoring of INR/effects of vitamin K antagonists in patients receiving concomitant ethacrynic acid. Anticoagulant dose reductions may be necessary. Conversely, monitor for decreased INR/effects of vitamin K antagonists with ethacrynic acid discontinuation.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case report describes a 38 year old female with a prothrombin time (PT) greater than 30 seconds on two different occasions while receiving concomitant administration of warfarin and ethacrynic acid.<sup>1</sup> Warfarin and acenocoumarol prescribing information both caution that concomitant administration of ethacrynic acid may potentiate their anticoagulant effects.<sup>2,3</sup> Ethacrynic acid may displace warfarin from plasma proteins which bind it and lead to increased warfarin systemic exposure.<sup>4</sup> Acenocoumarol is highly bound to plasma proteins and may similarly be affected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Petrick RJ, Kronacher N, Alcena V, “Interaction Between Warfarin and Ethacrynic Acid,” <i>JAMA</i>, 1975, 231(8): 843-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172754\">[PubMed 1172754]</a> </p>\n<p>2. Prescribing information. Coumadin (warfarin). Princeton, NJ: Bristol-Myers Squibb, January 2010.</p>\n<p>3. Product Monograph. Sintrom (acenocoumarol). Montreal, Quebec, May 2009.</p>\n<p>4. Prescribing information. Edecrin (ethacrynic acid). Lawrenceville, NJ: Aton Pharma, April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5753":"<p><b>Title</b> Prochlorperazine / Deferoxamine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Deferoxamine may enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to prochlorperazine in patients receiving deferoxamine, due to a risk of temporary impairment of consciousness (potentially lasting for days) with the combination.</p> \n<p><b>Discussion</b> Prescribing information for deferoxamine states that coadministration with prochlorperazine may lead to temporary impairment of consciousness.<sup>1</sup> Two case reports have been published that describe loss of consciousness with the combination that lasted for 2-3 days (total prochlorperazine dose 20 - 25 mg).<sup>2</sup> Patients in these cases were reported to have fully recovered without any known long term adverse consequences. Notably, deferoxamine was used for treatment of rheumatoid disorders in these cases, in the absence of known iron or other cation excess. A small follow-up investigation in rats reproduced the reaction, with loss of consciousness for up to 36 hours observed in anemic rats fed iron deficient diets but shorter (12 hours or less) duration in rats fed normal diets.<sup>2</sup> The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Desferal (deferoxamine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2010.</p>\n<p>2. Blake DR, Winyard P, Lunec J, et al, “Cerebral and Ocular Toxicity Induced by Desferrioxamine,” <i>Q J Med</i>, 1985, 56(219):345-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4095247\">[PubMed 4095247]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5755":"<p><b>Title</b> CycloSPORINE (Systemic) / Ascorbic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ascorbic Acid may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum cyclosporine concentrations with ascorbic acid supplement initiation/dose increase.</p> \n<p><b>Discussion</b> In three clinical studies of cyclosporine maintained transplant recipients, antioxidant regimens containing ascorbic acid 500-1000 mg/day were associated with 24-30% lower trough cyclosporine concentrations compared to baseline values or placebo treatment.<sup>1,2,3</sup> All regimens also contained vitamin E (267-500 mg/day) and one contained beta carotene (6 mg/day). The mechanism of this interaction is unknown, and it is unclear whether the observed changes may be attributable to ascorbic acid or the other supplements.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lake KD, Aaronson KD, Gorman LE, et al, “Effect of Oral Vitamin E and C Therapy on Calcineurin Inhibitor Levels in Heart Transplant Recipients,” <i>J Heart Lung Transplant</i>, 2005, 24(8):990-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16102431\">[PubMed 16102431]</a></p>\n<p>2. Blackhall ML, Fassett RG, Sharman JE, et al, “Effects of Antioxidant Supplementation on Blood Cyclosporine A and Glomerular Filtration Rate in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2005, 20(9):1970-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15998657\">[PubMed 15998657]</a></p>\n<p>3. de Vries AP, Oterdoom LH, Gans RO, et al, “Supplementation With Anti-oxidants Vitamin C and E Decreases Cyclosporine A Trough-Levels in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2006, 21(1):231-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115840\">[PubMed 16115840]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5756":"<p><b>Title</b> Belimumab / Monoclonal Antibodies</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of belimumab with other biologic therapies, such as other monoclonal antibodies, is not recommended.</p>\n<div>\n <p><b>Monoclonal Antibodies Interacting Members</b> Abciximab, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Alirocumab, Atezolizumab, Avelumab, Basiliximab, Belimumab, Benralizumab, Bevacizumab, Bezlotoxumab, Brentuximab Vedotin, Brodalumab, Canakinumab, Denosumab, Dinutuximab, Dupilumab, Durvalumab, Eculizumab, Elotuzumab, Emicizumab-kxwh, Evolocumab, Gemtuzumab Ozogamicin, Golimumab, Ibalizumab-uiyk, Ibritumomab Tiuxetan, InFLIXimab, Ixekizumab, Natalizumab, Nivolumab, Obinutuzumab, Ocrelizumab, Ofatumumab, Omalizumab, Palivizumab, Pertuzumab, Ramucirumab, Ranibizumab, Raxibacumab, RiTUXimab, Sarilumab, Secukinumab, Siltuximab, Tildrakizumab-asmn, Tocilizumab, Trastuzumab, Ustekinumab, Vedolizumab</p>\n</div> \n<p><b>Discussion</b> According to the belimumab prescribing information, since belimumab has not been studied in combination with other biologic agents, such concurrent use is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Benlysta (belimumab). Rockville, MD: Human Genome Sciences, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5757":"<p><b>Title</b> Belimumab / Abatacept</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Abatacept may enhance the adverse/toxic effect of Belimumab. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of belimumab with other biologic therapies, such as abatacept, is not recommended.</p> \n<p><b>Discussion</b> According to the belimumab prescribing information, since belimumab has not been studied in combination with other biologic agents, such concurrent use is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Benlysta (belimumab). Rockville, MD: Human Genome Sciences, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5759":"<p><b>Title</b> Belimumab / Etanercept</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Etanercept may enhance the adverse/toxic effect of Belimumab. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of belimumab with other biologic therapies, such as etanercept, is not recommended.</p> \n<p><b>Discussion</b> According to the belimumab prescribing information, since belimumab has not been studied in combination with other biologic agents, such concurrent use is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Benlysta (belimumab). Rockville, MD: Human Genome Sciences, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5763":"<p><b>Title</b> Bepridil / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Bepridil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of bepridil with tipranavir is contraindicated.</p> \n<p><b>Discussion</b> According to tipranavir prescribing information, concurrent use of bepridil is contraindicated due to the risk for increased bepridil concentrations leading to an increased possibility of toxicities such as dangerous arrhythmias.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5764":"<p><b>Title</b> Acyclovir-Valacyclovir / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Acyclovir-Valacyclovir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Acyclovir-Valacyclovir Interacting Members</b> Acyclovir (Systemic), ValACYclovir</p>\n</div> \n<p><b>Discussion</b> Acyclovir AUC was an average of 7% higher following administration of valacyclovir (500 mg x1) with steady-state tipranavir/ritonavir (500 mg/200 mg x 23 doses) in a study of 26 healthy volunteers.<sup>1</sup> Neither acyclovir maximum plasma concentrations nor tipranavir concentrations were significantly altered with this combination. This minimal increase in acyclovir exposure is deemed not to be of clinical significance.<sup>1,2</sup><br><br>The specific mechanism for this observed minimal pharmacokinetic change is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sabo JP, Cong XJ, Kraft MF, et al, “Lack of a Pharmacokinetic Interaction Between Steady-State Tipranavir/Ritonavir and Single-Dose Valacyclovir in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 2011, 67(3):277-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20963404\">[PubMed 20963404]</a></p>\n<p>2. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5766":"<p><b>Title</b> Toremifene / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of toremifene with strong CYP3A4 inhibitors should be avoided.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Toremifene AUC and maximum plasma concentration (Cmax) were increased by an average of 2.9- and 1.4-fold when toremifene (80 mg/day) was given with the strong CYP3A4 inhibitor ketoconazole (200 mg twice/day) in a study of 18 healthy volunteers.<sup>1</sup> Concentrations of the N-demethyltoremifene metabolite were significantly decreased.<br><br>The toremifene prescribing information states that concurrent use of toremifene with any strong CYP3A4 inhibitor should be avoided due to the risk for increased toremifene concentrations and the possibility for increased toxicity (primarily QT-prolongation and pro-arrhythmic effects).<sup>1</sup><br><br>In vivo and in vitro data support a major role for CYP3A4 in the metabolism of toremifene.<sup>1,2</sup> The likely mechanism for this interaction is inhibition of the CYP3A-mediated metabolism of toremifene.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fareston (toremifene). Memphis, TN: GTx, Inc., 03/2011.</p>\n<p>2. Berthou F, Dreano Y, Belloc C, et al, “Involvement of Cytochrome P450 3A Enzyme Family in the Major Metabolic Pathways of Toremifene in Human Liver Microsomes,” <i>Biochem Pharmacol</i>, 1994, 47(10):1883-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8204106\">[PubMed 8204106]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5767":"<p><b>Title</b> Toremifene / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Toremifene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor plasma calcium concentrations closely in patients receiving both toremifene and a thiazide diuretic, and note that use of this combination may increase the risk for hypercalcemia.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Toremifene prescribing information warns about the risk for hypercalcemia, which is a risk common to all antiestrogens.<sup>1</sup> Since thiazide diuretics decrease the renal excretion of calcium, toremifene prescribing information cautions that concurrent use of a thiazide diuretic with toremifene may increase the risk for hypercalcemia.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fareston (toremifene). Memphis, TN: GTx, Inc., 03/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5768":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Red Yeast Rice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Red Yeast Rice may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of red yeast rice with HMG-CoA reductase inhibitors. Any patient using this combination should be followed extra closely for signs/symptoms of HMG-CoA reductase inhibitor toxicity (e.g., myalgia, rhabdomyolysis, liver dysfunction, etc.).</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> Red yeast rice yeast is a natural product that contains several different active compounds that are structurally similar to the HMG-CoA reductase inhibitors (statins), including one in particular, monacolin K, which is identical to lovastatin. Though specific published studies examining the risks/benefits of using red yeast rice with a statin are not available, such concurrent use could be considered similar to using higher doses of either drug (due to similar effects/toxicities), potentially increasing the risk for adverse effects such as myopathy and liver dysfunction. In fact, several reviews of statin-related toxicities have consistently identified higher doses as a significant risk factor for toxicity.<sup>1,2,3</sup><br><br>Similar to the muscle toxicity risks with the statins, several case reports and case series have described myalgia/myopathy-related adverse effects asscociated with use of red yeast rice.<sup>4,5,6,7,8</sup> Reports that red yeast rice is well tolerated by patients with a history of statin-related adverse effects<sup>9,10</sup> may reflect the relatively low statin-equivalent dose of red yeast rice or may reflect some as of yet not fully understood difference in actions unique to red yeast rice.<br><br>One item that is particularly concerning with combinations involving red yeast rice is the reportedly large variation in monacolin content between identically-labeled red yeast rice products.<sup>11,12</sup> According to one study of 12 different red yeast rice products, total monacolin K (i.e., lovastatin) content varied between 0.1 mg to 10.09 mg per 600 mg capsule, and total monacolins varied from 0.31 mg to 11.15 mg per 600 mg capsule.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hedenmalm K, Alvan G, Ohagen P, et al, “Muscle Toxicity with Statins,” <i>Pharmacoepidemiol Drug Saf</i>, 2010, 19(3):223-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20014178\">[PubMed 20014178]</a></p>\n<p>2. Ucar M, Mjorndal T, Dahlqvist R, “HMG-CoA Reductase Inhibitors and Myotoxicity,” <i>Drug Saf</i>, 2000, 22(6):441-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10877038\">[PubMed 10877038]</a></p>\n<p>3. Backes JM, Howard PA, Ruisinger JF, et al, “Does Simvastatin Cause More Myotoxicity Compared with Other Statins?” <i>Ann Pharmacother</i>, 2009, 43(12):2012-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19920157\">[PubMed 19920157]</a></p>\n<p>4. Lapi F, Gallo E, Bernasconi S, et al, “Myopathies Associated with Red Yeast Rice and Liquorice: Spontaneous Reports from the Italian Surveillance System of Natural Health Products,” <i>Br J Clin Pharmacol</i>, 2008, 66(4):572-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18637891\">[PubMed 18637891]</a></p>\n<p>5. Anonymous, “Rhabdomyolysis Linked to Chinese Red Yeast Rice,” <i>Prescrire Int</i>, 2008, 17(94):64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18516816\">[PubMed 18516816]</a></p>\n<p>6. Polsani VR, Jones PH, Ballantyne CM, et al, “A Case Report of Myopathy from Consumption of Red Yeast Rice,” <i>J Clin Lipidol</i>, 2008, 2(1):60-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21291717\">[PubMed 21291717]</a></p>\n<p>7. Smith DJ, Olive KE, “Chinese Red Rice-Induced Myopathy,” <i>South Med J</i>, 2003, 96(12):1265-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14696880\">[PubMed 14696880]</a></p>\n<p>8. Prasad GV, Wong T, Meliton G, et al, “Rhabdomyolysis Due to Red Yeast Rice (Monascus purpureus) in a Renal Transplant Recipient,” <i>Transplantation</i>, 2002, 74(8):1200-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12438974\">[PubMed 12438974]</a></p>\n<p>9. Venero CV, Venero JV, Wortham DC, et al, “Lipid-Lowering Efficacy of Red Yeast Rice in a Population Intolerant to Statins,” <i>Am J Cardiol</i>, 2010, 105(5):664-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20185013\">[PubMed 20185013]</a></p>\n<p>10. Halbert SC, French B, Gordon RY, et al, “Tolerability of Red Yeast Rice (2,400 mg Twice Daily) Versus Pravastatin (20 mg Twice Daily) in Patients with Previous Statin Intolerance,” <i>Am J Cardiol</i>, 2010, 105(2):198-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102918\">[PubMed 20102918]</a></p>\n<p>11. Gordon RY, Cooperman T, Obermeyer W, et al, “Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products: Buyer Beware!” <i>Arch Intern Med</i>, 2010, 170(19):1722-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20975018\">[PubMed 20975018]</a></p>\n<p>12. Heber D, Lembertas A, Lu QY, et al, “An Analysis of Nine Proprietary Chinese Red Yeast Rice Dietary Supplements: Implications of Variability in Chemical Profile and Contents,” <i>J Altern Complement Med</i>, 2001, 7(2):133-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11327519\">[PubMed 11327519]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5769":"<p><b>Title</b> Bisphosphonate Derivatives / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Consider carefully the need for proton pump inhibitor therapy in patients being treated with a bisphosphonate derivative, and/or limit the proton pump inhibitor dose/duration of therapy when appropriate. H2-receptor antagonists do not appear to confer the same risk for this possible interaction. Older patients and those using higher doses of proton pump inhibitors appear to be at greatest risk.</p>\n<div>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Pamidronate, Risedronate, Tiludronate, Zoledronic Acid</p>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> According to a cohort study of more than 38,000 alendronate users who were followed for an average of 3.5 years, concurrent use of a proton pump inhibitor (PPI) was associated with a significant decrease in the hip fracture-protection of alendronate.<sup>1</sup> Among non-PPI-users, there was a significant 39% reduction in the risk for hip fracture associated with alendronate use; conversely, among PPI-users, there was only a non-significant 19% reduction in the hip fracture risk with alendronate. Both older patients (particularly those over 70 years of age) and those taking higher doses of a PPI appeared to be at a particularly high risk for decreased alendronate fracture protection.<sup>1</sup> Several analyses of case reports/case series of atypical fractures among bisphophonate users have similarly identified PPI use as a risk factor for the occurrence of these fractures.<sup>2,3,4</sup> Also, a retrospective cohort study found an increased risk of hip fractures and overall fracture risk associated with concurrent PPI use among bisphosphonate users, and an increased risk of hip, spine, or any fracture among all PPI users.<sup>5</sup> These data are somewhat supported by the many studies that have found associations between PPI use and an increased fracture risk,<sup>6,7,8,9,10,11,12</sup> with some even documenting a dose- and/or duration-dependency of the observed risk.<sup>8,10,11,12</sup><br><br>In contrast to these findings, a post-hoc analysis of 2,729 risedronate- and 2,725 placebo-treated subjects, including 8.8% of whom were also receiving an acid-suppressing medication, found no difference in the fracture-protecting effects of risedronate according to PPI use.<sup>13</sup> Several other studies have also failed to find a significant link between PPI use (independent of bisphosphonate use) and the risk for clinical fractures<sup>14,15,16</sup> or changes in bone mineral density.<sup>17</sup><br><br>The specific mechanism for any PPI-associated decrease in bisphosphonate protection is uncertain, though several possible mechanisms have been proposed, including both direct effects of PPIs on the bone and more indirect effects (e.g., decreased absorption of calcium, magnesium, vitamin B12, etc.).<sup>1,18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” <i>Arch Intern Med</i>, 2011, 171(11):998-1004. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21321287\">[PubMed 21321287]</a></p>\n<p>2. Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” <i>Endokrynol Pol</i>, 2011, 62(1):84-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21365585\">[PubMed 21365585]</a></p>\n<p>3. Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” <i>Bone</i>, 2010, 47(2):169-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20493982\">[PubMed 20493982]</a></p>\n<p>4. Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” <i>Drug Saf</i>, 2009, 32(9):775-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19670917\">[PubMed 19670917]</a></p>\n<p>5. de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” <i>Osteoporos Int</i>, 2009, 20(12):1989-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19333676\">[PubMed 19333676]</a></p>\n<p>6. Ngamruengphong S, Leontiadis GI, Radhi S, et al, “Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies,” <i>Am J Gastroenterol</i>, 2011, Apr 12 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21483462\">[PubMed 21483462]</a></p>\n<p>7. Kwok CS, Yeong JK, Loke YK, “Meta-Analysis: Risk of Fractures with Acid-Suppressing Medication,” <i>Bone</i>, 2011, 48(4):768-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21185417\">[PubMed 21185417]</a></p>\n<p>8. Chiu HF, Huang YW, Chang CC, et al, “Use of Proton Pump Inhibitors Increased the Risk of Hip Fracture: A Population-Based Case-Control Study,” <i>Pharmacoepidemiol Drug Saf</i>, 2010, 19(11):1131-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20872906\">[PubMed 20872906]</a></p>\n<p>9. Gray SL, LaCroix AZ, Larson J, et al, “Proton Pump Inhibitor Use, Hip Fracture, and Change in Bone Mineral Density in Postmenopausal Women: Results from the Women's Health Initiative,” <i>Arch Intern Med</i>, 2010, 170(9):765-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20458083\">[PubMed 20458083]</a></p>\n<p>10. Corley DA, Kubo A, Zhao W, et al, “Proton Pump Inhibitors and Histamine-2 Receptor Antagonists are Associated with Hip Fractures Among At-Risk Patients,” <i>Gastroenterology</i>, 2010, 139(1):93-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20353792\">[PubMed 20353792]</a></p>\n<p>11. Targownik LE, Lix LM, Metge CJ, et al, “Use of Proton Pump Inhibitors and Risk of Osteoporosis-Related Fractures,” <i>CMAJ</i>, 2008, 179(4):319-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18695179\">[PubMed 18695179]</a></p>\n<p>12. Yang YX, Lewis JD, Epstein S, et al, “Long-Term Proton Pump Inhibitor Therapy and Risk of Hip Fracture,” <i>JAMA</i>, 2006, 296(24):2947-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17190895\">[PubMed 17190895]</a></p>\n<p>13. Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” <i>Osteoporos Int</i>, 2012, 23(1):277-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21365461\">[PubMed 21365461]</a></p>\n<p>14. Bodmer M, Meier C, Kraenzlin ME, et al, “Proton Pump Inhibitors and Fracture Risk: True Effect or Residual Confounding?” <i>Drug Saf</i>, 2010, 33(10):843-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20812769\">[PubMed 20812769]</a></p>\n<p>15. Pouwels S, Lalmohamed A, Souverein P, et al, “Use of Proton Pump Inhibitors and Risk of Hip/Femur Fracture: A Population-Based Case-Control Study,” <i>Osteoporos Int</i>, 2011, 22(3):903-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20585937\">[PubMed 20585937]</a></p>\n<p>16. Kaye JA, Jick H, “Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients Without Major Risk Factors,” <i>Pharmacotherapy</i>, 2008, 28(8):951-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18657011\">[PubMed 18657011]</a></p>\n<p>17. Targownik LE, Lix LM, Leung S, et al, “Proton-Pump Inhibitor Use is Not Associated with Osteoporosis or Accelerated Bone Mineral Density Loss,” <i>Gastroenterology</i>, 2010, 138(3):896-904. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19931262\">[PubMed 19931262]</a></p>\n<p>18. Hyun JJ, Chun HJ, Keum B, et al, “Effect of Omeprazole on the Expression of Transcription Factors in Osteoclasts and Osteoblasts,” <i>Int J Mol Med</i>, 2010, 26(6):877-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21042782\">[PubMed 21042782]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5777":"<p><b>Title</b> Vitamin K Antagonists / Chloral Hydrate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloral Hydrate may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased effects of vitamin K antagonists (e.g., prothrombin time/INR, and signs and symptoms of bleeding) with initiation/dose increase of chloral hydrate. The risk for increased effects of vitamin K antagonists are thought to be transient, occuring within the first few weeks following initiation of chloral hydrate. Temporary dose reductions of the vitamin K antagonist may be necessary. Monitor for decreased effects of vitamin K antagonists with discontinuation/dose decrease of chloral hydrate.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The warfarin dose requirement on days 2 to 4 of therapy was an average of 31% lower among patients receiving daily chloral hydrate for the first 4 days of warfarin therapy (n=32) as compared to those patients not receiving any chloral hydrate during the first 4 days (n=67) as part of a retrospective review.<sup>1</sup> The dose requirement on days 2 to 4 was an average of 17% lower among patients receiving only 1 to 3 doses of chloral hydrate during the first 4 days of warfarin. Both the warfarin loading dose and the warfarin maintenance dose were not different among the groups. This is similar to other reports describing a transient increase in warfarin effects with concurrent use of chloral hydrate.<sup>2,3</sup><br><br>Conversely, several other studies have reported no evidence of a significant interaction between chloral hydrate and warfarin, including specifically a lack of any evidence for even a transient interaction.<sup>3,4,5</sup><br><br>The mechanism of any potential interaction is uncertain, but displacement of warfarin from its protein binding sites by a highly-bound chloral hydrate metabolite may be at least partially responsible for any transient increase in warfarin effects. Some chloral hydrate labeling warns that a transient enhancement of coumarin hypoprothrombinemic effects may occur within the first two weeks of therapy due to displacement of the anticoagulant from plasma binding proteins.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Interaction between chloral hydrate and warfarin. A report from the Boston Collaborative Drug Surveillance Program, Boston Universtiy Medical Center. <i>N Engl J Med</i>. 1972;286(2):53-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5006877\">[PubMed 5006877]</a></p>\n<p>2. Sellers EM, Koch-Weser J. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. <i>N Engl J Med</i>. 1970;283(16):827-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5458032\">[PubMed 5458032]</a></p>\n<p>3. Koch-Weser J, Sellers EM, Udall JA, Griner PF, Rickles FR. Chloral hydrate and warfarin therapy. <i>Ann Intern Med</i>. 1971;75(1):141-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5091561\">[PubMed 5091561]</a></p>\n<p>4. Udall JA. Warfarin-chloral hydrate interaction. Pharmacological activity and clinical significance. <i>Ann Intern Med</i>. 1974;81(3):341-344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4855407\">[PubMed 4855407]</a></p>\n<p>5. Griner PF, Raisz LG, Rickles FR, Wiesner PJ, Odoroff CL. Chloral hydrate and warfarin interaction: clinical significance. <i>Ann Intern Med</i>. 1971;74(4):540-543. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4927901\">[PubMed 4927901]</a></p>\n<p>6. pms-Chloral hydrate [product monograph]. Montreal, Canada: Pharmascience Inc.; May 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5778":"<p><b>Title</b> Aluminum Hydroxide / Vitamin D Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.</p>\n<div>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcipotriene, Calcitriol (Systemic), Calcitriol (Topical), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol, Tacalcitol</p>\n</div> \n<p><b>Discussion</b> The paricalcitol prescribing information specifically cautions that excessive and/or chronic concurrent use of aluminum salts and other aluminum-containing products should be avoided due to an increased risk for aluminum accumulation/toxicity.<sup>1</sup> Several human studies and animal studies have shown that vitamin D enhances aluminum absorption.<sup>2,3,4,5,6,7,8</sup> Given the apparent relationship between vitamin D and aluminum absorption, this risk likely extends to all vitamin D analogs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011.</p>\n<p>2. Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” <i>CMAJ</i>, 1992, 147(9):1308, 1313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1340782\">[PubMed 1340782]</a></p>\n<p>3. Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” <i>Clin Nephrol</i>, 1989, 31(3):123-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706809\">[PubMed 2706809]</a></p>\n<p>4. Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” <i>Clin Nephrol</i>, 1986, 26(3):146-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769230\">[PubMed 3769230]</a></p>\n<p>5. Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” <i>Proc Eur Dial Transplant Assoc Eur Ren Assoc</i>, 1985, 21:390-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3991529\">[PubMed 3991529]</a></p>\n<p>6. Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” <i>Am J Physiol</i>, 1985, 249(2 Pt 1):G209-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4025548\">[PubMed 4025548]</a></p>\n<p>7. Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” <i>J Environ Sci Health B</i>, 1986, 21(2):191-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3011882\">[PubMed 3011882]</a></p>\n<p>8. Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” <i>J Lab Clin Med</i>, 1986, 108(2):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3755457\">[PubMed 3755457]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5779":"<p><b>Title</b> Sucralfate / Vitamin D Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.</p>\n<div>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcipotriene, Calcitriol (Systemic), Calcitriol (Topical), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol, Tacalcitol</p>\n</div> \n<p><b>Discussion</b> The paricalcitol prescribing information specifically cautions that excessive and/or chronic concurrent use of aluminum salts and other aluminum-containing products, such as sucralfate, should be avoided due to an increased risk for aluminum accumulation/toxicity.<sup>1</sup> Several human studies and animal studies have shown that vitamin D enhances aluminum absorption.<sup>2,3,4,5,6,7,8</sup> Given the apparent relationship between vitamin D and aluminum absorption, this risk likely extends to all vitamin D analogs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011.</p>\n<p>2. Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” <i>CMAJ</i>, 1992, 147(9):1308, 1313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1340782\">[PubMed 1340782]</a></p>\n<p>3. Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” <i>Clin Nephrol</i>, 1989, 31(3):123-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706809\">[PubMed 2706809]</a></p>\n<p>4. Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” <i>Clin Nephrol</i>, 1986, 26(3):146-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769230\">[PubMed 3769230]</a></p>\n<p>5. Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” <i>Proc Eur Dial Transplant Assoc Eur Ren Assoc</i>, 1985, 21:390-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3991529\">[PubMed 3991529]</a></p>\n<p>6. Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” <i>Am J Physiol</i>, 1985, 249(2 Pt 1):G209-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4025548\">[PubMed 4025548]</a></p>\n<p>7. Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” <i>J Environ Sci Health B</i>, 1986, 21(2):191-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3011882\">[PubMed 3011882]</a></p>\n<p>8. Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” <i>J Lab Clin Med</i>, 1986, 108(2):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3755457\">[PubMed 3755457]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5780":"<p><b>Title</b> SORAfenib / Acetaminophen</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> As possible, consider less frequent and/or lower daily doses of acetaminophen in patients who are also taking sorafenib. Patients exposed to this combination, and particularly those with greater acetaminophen exposure, should be monitored for signs/symptoms of liver toxicity.</p> \n<p><b>Discussion</b> A case report describes fatal liver toxicity associated with concurrent use of sunitinib, acetaminophen, and levothyroxine.<sup>1</sup> Though levothyroxine may have been the immediate precipitant of the observed toxicity in this case, it is suspected that concurrent use of sunitinib and acetaminophen contributed. Another published report describes a case of fatal liver toxicity associated with concurrent use of the tyrosine kinase inhibitor imatininb and acetaminophen.<sup>2</sup> Similarly, a study in mice found evidence of more hepatic toxicity with concurrent use of imatinib and acetaminophen than with either drug alone.<sup>3</sup><br><br>Although it is not certain what role, if any, acetaminophen had in these cases (since both imatinib and sunitinib have been independently associated with hepatotoxicity), National Comprehensive Cancer Network practice guidelines for CML include a warning concerning the potential acetaminophen--imatinib interaction and recommend a maximum acetaminophen dose of 1300 mg per day for patients receiving imatinib.<sup>4</sup> No such specific recommendation is included for sunitinib, but limiting the acetaminophen dose when possible certainly appears to be a prudent preventive measure.<br><br>The mechanism by which certain tyrosine kinase inhibitors such as sunitinib or imatinib may interact with acetaminophen to cause a greater risk of hepatotoxicity is uncertain. An in vitro study using human liver microsomes concluded that dasatinib, imatinib, and sunitinib were all potent inhibitors of acetaminophen glucuronidation,<sup>5</sup> suggesting a possible pharmacokinetic mechanism for the observed interaction. In contrast, single-dose (1000 mg) acetaminophen pharmacokinetics were not significantly altered when administered following pre-treatment with imatinib (400 mg/day x 7 days) (n=12).<sup>6</sup> Evidence for more of a pharmacodynamic mechanism for this apparent interaction is also available. An in vitro study of dasatinib metabolism concluded that dasatinib metabolism results in the formation of a highly reactive intermediate, similar to that formed from acetaminophen metabolism.<sup>7</sup> Formation of such a reactive metabolite could result in excessive hepatocellular damage, particularly when given with another hepatotoxic agent such as acetaminophen.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Weise AM, Liu CY, Shields AF, “Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and Levothyroxine,” <i>Ann Pharmacother</i>, 2009, 43(4):761-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336648\">[PubMed 19336648]</a></p>\n<p>2. Ridruejo E, Cacchione R, Villamil AG, et al, “Imatinib-Induced Fatal Acute Liver Failure,” <i>World J Gastroenterol</i>, 2007, 13(48):6608-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18161937\">[PubMed 18161937]</a></p>\n<p>3. Nassar I, Pasupati T, Judson JP, et al, “Histopathological Study of the Hepatic and Renal Toxicity Associated with the Co-administration of Imatinib and Acetaminophen in a Preclinical Mouse Model,” <i>Malays J Pathol</i>, 2010, 32(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20614720\">[PubMed 20614720]</a></p>\n<p>4. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. V.2.2009. Available through www.nccn.org (accessed 10/27/2008).</p>\n<p>5. Liu Y, Ramirez J, Ratain MJ, “Inhibition of Acetaminophen Glucuronidation by Tyrosine Kinase Inhibitors,” <i>Br J Clin Pharmacol</i>, 2011, Jan 14 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21235620\">[PubMed 21235620]</a></p>\n<p>6. Kim DW, Tan EY, Jin Y, et al, “Effects of Imatinib Mesylate on the Pharmacokinetics of Paracetamol (Acetaminophen) in Korean Patients with Chronic Myelogenous Leukaemia,” <i>Br J Clin Pharmacol</i>, 2011, 71(2):199-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21219400\">[PubMed 21219400]</a></p>\n<p>7. Li X, He Y, Ruiz CH, Koenig M, et al, “Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways,” <i>Drug Metab Dispos</i>, 2009, 37(6):1242-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19282395\">[PubMed 19282395]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5781":"<p><b>Title</b> Dasatinib / Acetaminophen</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> As possible, consider less frequent and/or lower daily doses of acetaminophen in patients who are also taking dasatinib. Patients exposed to this combination, and particularly those with greater acetaminophen exposure, should be monitored for signs/symptoms of liver toxicity.</p> \n<p><b>Discussion</b> An in vitro study using human liver microsomes concluded that the tyrosine kinase inhibitors dasatinib, imatinib, and sunitinib were all potent inhibitors of acetaminophen glucuronidation,<sup>1</sup> suggesting a possible pharmacokinetic interaction between these agents and acetaminophen. Evidence for more of a pharmacodynamic mechanism for this apparent interaction is also available. An in vitro study of dasatinib metabolism concluded that dasatinib metabolism results in the formation of a highly reactive intermediate, similar to that formed from acetaminophen metabolism.<sup>2</sup> Formation of such a reactive metabolite could result in excessive hepatocellular damage, particularly when given with another hepatotoxic agent such as acetaminophen.<br><br>Though the clinical significance of these in vitro findings are not clear, case reports have described fatal hepatotoxicity associated with acetaminophen-imatinib and acetaminophen-sunitinib-levothyroxine.<sup>3,4</sup> Also, a study in mice found evidence of more hepatic toxicity with concurrent use of imatinib and acetaminophen than with either drug alone.<sup>5</sup> Although it is not certain what role, if any, acetaminophen had in these cases (since both imatinib and sunitinib have been independently associated with hepatotoxicity), National Comprehensive Cancer Network practice guidelines for CML do include a warning concerning the potential acetaminophen--imatinib interaction and recommend a maximum acetaminophen dose of 1300 mg per day for patients receiving imatinib.<sup>6</sup> No such specific recommendation is included for sunitinib or dasatinib, but limiting the acetaminophen dose when possible certainly appears to be a prudent preventive measure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu Y, Ramirez J, Ratain MJ, “Inhibition of Acetaminophen Glucuronidation by Tyrosine Kinase Inhibitors,” <i>Br J Clin Pharmacol</i>, 2011, Jan 14 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21235620\">[PubMed 21235620]</a></p>\n<p>2. Li X, He Y, Ruiz CH, Koenig M, et al, “Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways,” <i>Drug Metab Dispos</i>, 2009, 37(6):1242-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19282395\">[PubMed 19282395]</a></p>\n<p>3. Weise AM, Liu CY, Shields AF, “Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and Levothyroxine,” <i>Ann Pharmacother</i>, 2009, 43(4):761-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336648\">[PubMed 19336648]</a></p>\n<p>4. Ridruejo E, Cacchione R, Villamil AG, et al, “Imatinib-Induced Fatal Acute Liver Failure,” <i>World J Gastroenterol</i>, 2007, 13(48):6608-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18161937\">[PubMed 18161937]</a></p>\n<p>5. Nassar I, Pasupati T, Judson JP, et al, “Histopathological Study of the Hepatic and Renal Toxicity Associated with the Co-administration of Imatinib and Acetaminophen in a Preclinical Mouse Model,” <i>Malays J Pathol</i>, 2010, 32(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20614720\">[PubMed 20614720]</a></p>\n<p>6. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. V.2.2009. Available through www.nccn.org (accessed 10/27/2008).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5782":"<p><b>Title</b> Vandetanib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vandetanib. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required. At least one non-US label for vandetanib does recommend considering drugs with no or minimal CYP3A4 inhibition due to the potential for a significant interaction.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The average vandetanib AUC was increased by 9% when vandetanib (single 300 mg dose on day 4) was administered to healthy volunteers (n=16) who were receiving the strong CYP3A4 inhibitor itraconazole (200 mg/day, days 1-24).<sup>1</sup> Though this increase in vandetanib was statistically significant, it was deemed to be of little clinical significance, and the US vandetanib prescribing information recommends no adjustment to therapy with concurrent CYP3A4 inhibitors.<sup>2</sup> In contrast, at least one non-US label for vandetanib states that alternatives with no or minimal CYP3A4 inhibition should be considered.<sup>3</sup><br><br>Vandetanib is partially metabolized by CYP3A, but other enzymes and non-metabolic elimination also appear to be involved in the drug's clearance.<sup>2</sup> This variable elimination likely explains the relatively minor interaction observed with itraconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Martin P, Oliver S, Robertson J, et al. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. <i>Drugs R D</i>. 2011;11(1):37-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21410294\">[PubMed 21410294]</a></p>\n<p>2. Caprelsa (vandetanib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2011.</p>\n<p>3. Caprelsa (vandetanib) [product monograph]. Mississauga, Ontario, Canada: Genzyme Canada; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5783":"<p><b>Title</b> Vandetanib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of vandetanib and any strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The average vandetanib AUC was reduced by 40% when vandetanib (300 mg x1 on day 10) was administered to healthy volunteers (n=18) taking rifampin (600 mg/day, days 1-31).<sup>1</sup> The vandetanib maximum serum concentration (Cmax) was not significantly changed, but the average AUC and Cmax of the N-desmethyl metabolite were increased by 266% and 414%, respectively.<br><br>As a result of these data, the vandetanib prescribing information recommends against concurrent use of vandetanib with any strong CYP3A4 inducer.<sup>2</sup><br><br>Considering these study data and evidence that CYP3A is at least partly responsible for the N-demethylation of vandetanib,<sup>2</sup> CYP3A induction by rifampin is the likely mechanism for the observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Martin P, Oliver S, Robertson J, et al, “Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole,” <i>Drugs R D</i>, 2011, 11(1):37-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21410294\">[PubMed 21410294]</a></p>\n<p>2. Prescribing information. Vandetanib. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5784":"<p><b>Title</b> Vandetanib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Vandetanib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of vandetanib and St Johns wort.</p> \n<p><b>Discussion</b> The vandetanib prescribing information recommends against concurrent use of vandetanib with St Johns wort or any strong CYP3A4 inducer.<sup>1</sup><br><br>Though specific data with St Johns wort are not available, the average vandetanib AUC was reduced by 40% when vandetanib (300 mg x1 on day 10) was administered to healthy volunteers (n=18) taking rifampin (600 mg/day, days 1-31).<sup>2</sup> The vandetanib maximum serum concentration (Cmax) was not significantly changed, but the average AUC and Cmax of the N-desmethyl metabolite were increased by 266% and 414%, respectively.<br><br>Considering these study data and evidence that CYP3A is at least partly responsible for the N-demethylation of vandetanib,<sup>1</sup> CYP3A induction by rifampin is the likely mechanism for the observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vandetanib. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 04/2011.</p>\n<p>2. Martin P, Oliver S, Robertson J, et al, “Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole,” <i>Drugs R D</i>, 2011, 11(1):37-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21410294\">[PubMed 21410294]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5786":"<p><b>Title</b> DOBUTamine / Ascorbic Acid</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction has only been demonstrated with intracoronary or jugular vein infusion of ascorbic acid. Other routes of administration are not expected to achieve the same local concentrations, and no interaction with dobutamine has been demonstrated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ascorbic Acid may enhance the positive inotropic effect of DOBUTamine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A clinical study of 19 healthy volunteers demonstrated an enhanced inotropic response to dobutamine (greater increase in left ventricular contractility) during intracoronary infusion of ascorbic acid (96 mg/min).<sup>1</sup> In a later study by the same investigators, there was no apparent modification of dobutamine effects in patients with heart failure (HF, average left ventricular ejection fraction [LVEF] 26%) receiving the same ascorbic acid regimen.<sup>2</sup> However, there was an increase in inotropic response to dobutamine when a second group of HF patients (average LVEF 24%) received intracoronary ascorbic acid in combination with the nitric oxide synthase inhibitor N-monomethyl-L-arginine.<sup>3</sup> A cohort of 19 patients with milder HF (average LVEF 39%) had increased inotropic response to dobutamine with infusion of ascorbic acid (2 mg bolus, followed by 50 mg/min continuous infusion) via the jugular vein, without concomitant administration of a nitric oxide synthase inhibitor.<sup>4</sup> <br><br>The exact mechanism of this interaction is unknown. HF is a condition associated with increases in reactive oxygen species (ROS) and markers of oxidative stress. The presence of ROS (specifically hydrogen peroxide) has been shown to attenuate cardiac beta adrenoceptor signaling.<sup>5</sup> Therefore, neutralization of ROS by ascorbic acid could theoretically increase sensitivity to dobutamine by enhancing cardiac beta adrenergic signal transduction in patients under oxidative stress. This effect may be negated by negative inotropic effects of nitric oxide and/or peroxynitrite<sup>6</sup> (formed by nitric oxide in the presence of ROS) in patients with more advanced disease and/or receiving certain concomitant medications. <br><br>These hypothetical mechanisms have not been confirmed and fail to fully explain the above clinical observations (in particular, why this interaction might occur in volunteers under minimal oxidative stress).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mak S and Newton GE, “Vitamin C Augments the Inotropic Response to Dobutamine in Humans With Normal Left Ventricular Function,” <i>Circulation</i>, 2001, 103(6):826-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11171790\">[PubMed 11171790]</a></p>\n<p>2. Mak S and Newton GE, “Redox Modulation of the Inotropic Response to Dobutamine is Impaired in Patients With Heart Failure,” <i>Am J Physiol Heart Circ Physiol</i>, 2004, 286(2):H789-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551049\">[PubMed 14551049]</a></p>\n<p>3. Mak S, Overgaard CB and Newton GE, “Effect of Vitamin C and L-NMMA on the Inotropic Response to Dobutamine in Patients With Heart Failure,” <i>Am J Physiol Heart Circ Physiol</i>, 2005, 289(6):H2424-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16040714\">[PubMed 16040714]</a></p>\n<p>4. Shinke T, Shite J, Takaoka H, et al, “Vitamin C Restores the Contractile Response to Dobutamine and Improves Myocardial Efficiency in Patients With Heart Failure After Anterior Myocardial Infarction,” <i>Am Heart J</i>, 2007, 154(4):645.e1-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17892985\">[PubMed 17892985]</a></p>\n<p>5. Persad S, Rupp H, Jindal R, et al, “Modification of Cardiac Beta-Adrenoceptor Mechanisms by H2O2,” <i>Am J Physiol</i>, 1998, 274(2 Pt 2):H416-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9486243\">[PubMed 9486243]</a></p>\n<p>6. Paulus WJ, Frantz S and Kelly RA, “Nitric Oxide and Cardiac Contractility in Human Heart Failure: Time for Reappraisal,” <i>Circulation</i>, 2001, 104(19):2260-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11696460\">[PubMed 11696460]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5787":"<p><b>Title</b> Vitamin K Antagonists / Neomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased anticoagulant effects (e.g., prothrombin time/INR, bleeding) with initiation of neomycin in patients receiving vitamin K antagonists. Monitor for decreased anticoagulant effects with discontinuation of neomycin.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Administration of neomycin (4 grams/day PO x 3 weeks) to 10 patients receiving fixed warfarin doses, increased the average weekly prothrombin time (PT) approximately 5.6 seconds (24.4 to 30 seconds) in 6 patients, but had no effect on PT in the other 4 patients.<sup>1</sup> The precise mechanism(s) for the observed change in PT are uncertain although the author suggests that a reduction of intestinal flora by neomycin may have contributed to the observations made. Warfarin U.S. prescribing information and acenocoumarol Canadian product monograph both caution that concurrent use with neomycin may potentiate the anticoagulant effects of these agents.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Udall JA, “Human Sources and Absorption of Vitamin K in Relation to Anticoagulation Stability,” <i>JAMA</i>, 1965, 194(2): 127-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5897315\">[PubMed 5897315]</a></p>\n<p>2. Prescribing information. Coumadin (warfarin). Princeton, NJ: Bristol-Myers Squibb, January 2010.</p>\n<p>3. Product monograph. Sintrom (acenocoumarol). Montreal, Quebec: Paladin Labs Inc., May 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5788":"<p><b>Title</b> Theophylline / Deferasirox</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Deferasirox may increase the serum concentration of Theophylline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of deferasirox and theophylline when possible. If this combination must be used, consider reducing the theophylline dose, and monitor patients closely for signs/symptoms of toxicity and serum theophylline concentrations.</p> \n<p><b>Discussion</b> According to deferasirox prescribing information, the theophylline AUC and elimination half-life were each approximately doubled following the administration of a single theophylline dose (120 mg) to healthy volunteers who had been receiving deferasirox (30 mg/kg/day).<sup>1</sup> Due to the narrow therapeutic index of theophylline, concurrent use of deferasirox and theophylline should be avoided when possible.<sup>1</sup><br><br>The mechanism of this apparent interaction is unclear, but deferasirox-mediated inhibition of the CYP1A2 metabolism of theophylline is suspected.<sup>1</sup> Consequently, caution with concurrent use of any other CYP1A2 substrate (especially high-risk or narrow therapeutic index agents) with deferasirox is recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5789":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inhibitors) / Deferasirox</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Deferasirox may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of any CYP1A2 substrate and deferasirox. Monitor patients closely for signs/symptoms of toxicity associated with the CYP1A2 substrate and consider avoiding the use of CYP1A2 substrates that have a narrow therapeutic index (eg, theophylline, tizanidine).</p>\n<div>\n <p><b>CYP1A2 Substrates (High risk with Inhibitors) Interacting Members</b> Acebrophylline, Acenocoumarol, Agomelatine, Alosetron, Aminophylline, Asenapine, Bromazepam, Caffeine, ClomiPRAMINE, CloZAPine, Cyclobenzaprine, Dacarbazine, DULoxetine, Flutamide, FluvoxaMINE, Kola Nut, Lidocaine (Systemic), Lidocaine (Topical), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Pomalidomide, Propranolol, Ramelteon, Ramosetron, Rasagiline, ROPINIRole, Ropivacaine, Stiripentol, Tasimelteon, Theophylline, Thiothixene, TiZANidine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the deferasirox prescribing information, the theophylline AUC and elimination half-life were approximately doubled following the administration of a single theophylline dose (120 mg) to healthy volunteers who had been receiving deferasirox (30 mg/kg/day).<sup>1,2</sup> <br><br>The prescribing information recommends close monitoring for increased effects/toxicity of CYP1A2 substrates if coadministered with deferasirox, and to consider avoiding the use of CYP1A2 substrates that have a narrow therapeutic index (eg, theophylline, tizanidine).<sup>1,2</sup><br><br>The mechanism of this interaction is has not been fully investigated, but deferasirox-mediated inhibition of the CYP1A2 metabolism of theophylline is suspected.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Exjade</i> (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; October 2013.</p>\n<p>2. <i>Jadenu</i> (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5790":"<p><b>Title</b> Deferasirox / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the risk for gastrointestinal bleeding and irritation/ulceration associated with deferasirox, use caution when using with other drugs, such as the nonsteroidal anti-inflammatory drugs (NSAIDS), that can also cause gastrointestinal ulceration and/or bleeding. Monitor patients closely for evidence of gastrointestinal ulceration or bleeding.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Deferasirox use has been independently associated with gastrointestinal (GI) irritation, ulceration, and both fatal and nonfatal GI bleeding.<sup>1</sup> As a result, deferasirox prescribing information cautions that the risk for these toxicities may be increased with concurrent use of other drugs that can cause GI irritation or ulceration and/or increase the risk for bleeding. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, bisphosphonates, and anticoagulants are all specifically mentioned in this warning.<sup>1</sup> Caution and increased monitoring for signs/symptoms of GI toxicity are warranted with the use of any such combinations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5791":"<p><b>Title</b> Deferasirox / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the risk for gastrointestinal bleeding and irritation/ulceration associated with deferasirox, use caution when using with other drugs, such as the corticosteroids, that can also cause gastrointestinal ulceration and/or bleeding. Monitor patients closely for evidence of gastrointestinal ulceration or bleeding.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Deferasirox use has been independently associated with gastrointestinal (GI) irritation, ulceration, and both fatal and nonfatal GI bleeding.<sup>1</sup> As a result, deferasirox prescribing information cautions that the risk for these toxicities may be increased with concurrent use of other drugs that can cause GI irritation or ulceration and/or increase the risk for bleeding. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, bisphosphonates, and anticoagulants are all specifically mentioned in this warning.<sup>1</sup> Caution and increased monitoring for signs/symptoms of GI toxicity are warranted with the use of any such combinations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5792":"<p><b>Title</b> Deferasirox / Corticosteroids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the risk for gastrointestinal bleeding and irritation/ulceration associated with deferasirox, use caution when using with other drugs, such as the corticosteroids, that can also cause gastrointestinal ulceration and/or bleeding. Corticosteroids that are administered at higher doses and via routes that tend to result in higher systemic and/or gastrointestinal concentrations are more likely to result in a significant interaction. Monitor patients closely for evidence of gastrointestinal ulceration or bleeding.</p>\n<div>\n <p><b>Corticosteroids Interacting Members</b> Alclometasone, Amcinonide, Beclomethasone (Oral Inhalation), Beclomethasone (Topical), Betamethasone (Nasal), Betamethasone (Ophthalmic), Betamethasone (Systemic), Betamethasone (Topical), Budesonide (Oral Inhalation), Budesonide (Systemic), Budesonide (Topical), Ciclesonide (Oral Inhalation), Clobetasol, Clobetasone, Clocortolone, Corticotropin, Cortisone, Deflazacort, Desoximetasone, Dexamethasone (Systemic), Diflorasone, Diflucortolone, Fludrocortisone, Flunisolide (Oral Inhalation), Fluocinolone (Topical), Fluocinonide, Fluorometholone, Flurandrenolide, Fluticasone (Oral Inhalation), Fluticasone (Topical), Halcinonide, Halobetasol, Hydrocortisone (Systemic), Hydrocortisone (Topical), Medrysone, MethylPREDNISolone, Mometasone (Oral Inhalation), Mometasone (Topical), Prednicarbate, PrednisoLONE (Systemic), PrednisoLONE (Topical), PredniSONE, Rimexolone, Tixocortol Pivalate, Triamcinolone (Systemic), Triamcinolone (Topical)<br><b>Exceptions</b> Beclomethasone (Nasal), Budesonide (Nasal), Ciclesonide (Nasal), Desonide, Dexamethasone (Ophthalmic), Difluprednate, Flunisolide (Nasal), Fluocinolone (Ophthalmic), Fluticasone (Nasal), Hydrocortisone (Ophthalmic), Loteprednol, Mometasone (Nasal), PrednisoLONE (Ophthalmic), Triamcinolone (Nasal), Triamcinolone (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> Deferasirox use has been independently associated with gastrointestinal (GI) irritation, ulceration, and both fatal and nonfatal GI bleeding.<sup>1</sup> As a result, deferasirox prescribing information cautions that the risk for these toxicities may be increased with concurrent use of other drugs that can cause GI irritation or ulceration and/or increase the risk for bleeding. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, bisphosphonates, and anticoagulants are all specifically mentioned in this warning.<sup>1</sup> Caution and increased monitoring for signs/symptoms of GI toxicity are warranted with the use of any such combinations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5793":"<p><b>Title</b> Deferasirox / Bisphosphonate Derivatives</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction applies specifically to oral bisphosphonate derivatives.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the risk for gastrointestinal bleeding and irritation/ulceration associated with deferasirox, use caution when using with other drugs, such as the oral bisphosphonate derivatives, that can also cause gastrointestinal ulceration and/or bleeding. Monitor patients closely for evidence of gastrointestinal ulceration or bleeding.</p>\n<div>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Pamidronate, Risedronate, Tiludronate, Zoledronic Acid</p>\n</div> \n<p><b>Discussion</b> Deferasirox use has been independently associated with gastrointestinal (GI) irritation, ulceration, and both fatal and nonfatal GI bleeding.<sup>1</sup> As a result, deferasirox prescribing information cautions that the risk for these toxicities may be increased with concurrent use of other drugs that can cause GI irritation or ulceration and/or increase the risk for bleeding. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, bisphosphonates, and anticoagulants are all specifically mentioned in this warning.<sup>1</sup> Caution and increased monitoring for signs/symptoms of GI toxicity are warranted with the use of any such combinations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5794":"<p><b>Title</b> Deferasirox / Anticoagulants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the risk for gastrointestinal bleeding and irritation/ulceration associated with deferasirox, use caution when using with other drugs, such as anticoagulants, that can also cause gastrointestinal ulceration and/or bleeding. Monitor patients closely for evidence of gastrointestinal ulceration or bleeding.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Deferasirox use has been independently associated with gastrointestinal (GI) irritation, ulceration, and both fatal and nonfatal GI bleeding.<sup>1</sup> As a result, deferasirox prescribing information cautions that the risk for these toxicities may be increased with concurrent use of other drugs that can cause GI irritation or ulceration and/or increase the risk for bleeding. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, bisphosphonates, and anticoagulants are all specifically mentioned in this warning.<sup>1</sup> Caution and increased monitoring for signs/symptoms of GI toxicity are warranted with the use of any such combinations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5795":"<p><b>Title</b> Tetracyclines / Calcium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to concurrent use of oral tetracyclines and oral calcium salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the serum concentration of Tetracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> The absorption of tetracyclines may be impaired by concurrent use of calcium-containing antacids.<sup>1,2,3</sup> Considering that this interaction is likely the result of formation of a non-absorbable calcium-tetracycline complex, the interaction risk likely extends to concurrent use of any calcium-containing product, including calcium supplements and/or dietary calcium.<sup>4</sup> In fact a study in 12 healthy volunteers reported a significant decrease in tetracycline bioavailability with concurrent ingestion of a small amount of milk added to black coffee or black tea.<sup>5</sup><br><br>Though specific guidelines for managing this interaction have not been published, considering the nature of the interaction, separating the administration of calcium-containing products from the administration of the tetracycline derivative is likely to at least minimize the extent of the interaction when complete avoidance of the combination is not possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tetracycline. Sellersville, PA: Teva Pharmaceuticals USA, 6/2009.</p>\n<p>2. Prescribing information. Minocin (minocycline). Cranford, NJ: Triax Pharmaceuticals, LLC, 08/2010.</p>\n<p>3. Prescribing information. Vibramycin (doxycycline). New York, NY: Pfizer Inc, April 2007.</p>\n<p>4. Prescribing information. PhosLo (calcium acetate). Waltham, MA: Fresenius Medical Care North America, 3/2011.</p>\n<p>5. Jung H, Peregrina AA, Rodriguez JM, et al, “The Influence of Coffee with Milk and Tea with Milk on the Bioavailability of Tetracycline,” <i>Biopharm Drug Dispos</i>, 1997, 18(5):459-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9210983\">[PubMed 9210983]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5796":"<p><b>Title</b> Calcium Acetate / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n</div> \n<p><b>Discussion</b> Calcium acetate prescribing information cautions against concurrent use of other calcium-containing products due to the risk for hypercalcemia, particularly in high-risk patient populations, such as those patients with end-stage renal disease, that may be taking calcium acetate as a phosphate binder.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. PhosLo (calcium acetate). Waltham, MA: Fresenius Medical Care North America, 3/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5797":"<p><b>Title</b> Acarbose / Neomycin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction applies only to orally administered neomycin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor the clinical response to acarbose closely when used together with oral neomycin. This combination may result in an enhanced suppression of postprandial glucose concentrations, and/or in an increase in gastrointestinal side effects of acarbose. A reduction in acarbose dose may be necessary.</p> \n<p><b>Discussion</b> Concurrent use of oral neomycin with acarbose may be associated with an increase in acarbose effects and toxicity.<sup>1</sup> By targeting intestinal flora, oral neomycin may inhibit the metabolism of acarbose, which is a process normally mediated largely by intestinal bacteria,<sup>2</sup> leading to increases in acarbose half-life and enhanced actions/toxicities. If this results in a severe increase in gastrointestinal toxicity, a temporary acarbose dose reduction may be necessary.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Precose (acarbose) tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) - March 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm250694.htm (<i>Accessed 4/25/2011</i>)</p>\n<p>2. Prescribing information. Precose (acarbose). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 03/11.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5798":"<p><b>Title</b> Ritonavir / QuiNINE</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear. QuiNINE may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of QuiNINE. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of quinine with ritonavir.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, the average AUC and maximum serum concentration (Cmax) of quinine increased approximately 4-fold when quinine (600 mg quinine sulfate single oral dose) was given on the 8th day of ritonavir administration (200 mg every 12 hours).<sup>1</sup> In a second study, in 13 healthy volunteers the quinine (648 mg quinine sulfate single oral dose) AUC and Cmax actually decreased by around 50% when given on the 12th day of lopinavir/ritonavir (400/100 mg twice daily).<sup>2</sup> 3-hydroxyquinine AUC and Cmax decreased by approximately 70%.<sup>2</sup><br><br>The specific mechanisms of these interactions are uncertain, as is the reason for the differing results seen with ritonavir and lopinavir/ritonavir. Quinine is a substrate of CYP3A4 and P-glycoprotein, both of which are inhibited by lopinavir and ritonavir. Ritonavir also induces CYP3A. Quinine prescribing information recommends avoiding concurrent use of ritonavir and quinine.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Soyinka JO, Onyeji CO, Omoruyi SI, et al, “Pharmacokinetic Interactions Between Ritonavir and Quinine in Healthy Volunteers Following Concurrent Administration,” <i>Br J Clin Pharmacol</i>, 2010, 69(3):262-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233197\">[PubMed 20233197]</a></p>\n<p>2. Nyunt MM, Lu Y, Yu Q, et al, “Effects of Ritonavir-Boosted Lopinavir on the Pharmacokinetics of Quinine,” <i>Clin Pharmacol Ther</i>, 2012, 91(5):889-95. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22472986\">[PubMed 22472986]</a></p>\n<p>3. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5799":"<p><b>Title</b> Halofantrine / QuiNINE</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> QuiNINE may enhance the adverse/toxic effect of Halofantrine. QuiNINE may increase the serum concentration of Halofantrine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of quinine and halofantrine should be avoided.</p> \n<p><b>Discussion</b> In vitro data suggest that quinine may inhibit the metabolism of halofantrine leading to increased concentrations of halofantrine, and a possible increase in toxicity.<sup>1</sup><br><br>Due to both the inherent QT-prolonging potential of halofantrine and the potential for quinine to increase halofantrine concentrations, concurrent use of these drugs should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}